CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10873994,108739942,2,F,20141204,20190918,20150227,20190923,EXP,,ZA-009507513-1412ZAF004514,MERCK,,9,YR,,F,Y,22.65,KG,20190923,,CN,ZA,ZA,EFAVIRENZ.,Aspartate aminotransferase increased,108739942,OT,,,108739942,1,20141118,20141124,,,108739942,1,Antiretroviral therapy
11991033,119910336,6,F,,20190904,20160202,20190916,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190916,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,119910336,OT,,,,,,,,,119910336,1,Product used for unknown indication
12161166,121611665,5,F,,20190816,20160308,20190820,EXP,,CA-ABBVIE-10P-163-0641882-00,ABBVIE,"PFEFFER G, COTE H, MONTANER J, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009 JUL;73:71-72.",52,YR,,M,Y,,,20190820,,MD,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,121611665,OT,,,121611665,1,200802,200802,,,121611665,1,HIV infection
12975593,129755932,2,F,,20161117,20161125,20190722,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-100018,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722,,OT,US,US,EFAVIRENZ.,Drug interaction,129755932,OT,,,,,,,,,129755932,1,HIV infection
13877993,138779934,4,F,,20190726,20170817,20190805,EXP,,BW-GILEAD-2017-0288038,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKAMN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,F,Y,,,20190805,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,138779934,OT,,,,,,,,,138779934,1,HIV infection
13878029,138780294,4,F,,20190726,20170817,20190805,EXP,,BW-GILEAD-2017-0288039,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACOSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,N,,Y,,,20190805,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death neonatal;Foetal exposure during pregnancy,138780294,DE,,,,,,,,,138780294,1,HIV infection
13878060,138780603,3,F,,20190726,20170817,20190805,EXP,,BW-GILEAD-2017-0288037,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,,Y,,,20190805,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,138780603,OT,,,,,,,,,138780603,1,HIV infection
14108835,141088352,2,F,,20190726,20171019,20190805,EXP,,BW-GILEAD-2017-0288035,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,F,Y,,,20190805,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature baby,141088352,OT,,,,,,,,,141088352,1,HIV infection
14121936,141219364,4,F,20150430,20190711,20171024,20190924,EXP,,UG-MYLANLABS-2017M1066016,MYLAN,,37,YR,,F,Y,,,20190924,,MD,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Headache;Hypertension;Metrorrhagia;Pre-eclampsia;Uterine hypotonus,141219364,HO,,,141219364,4,20150608,20150608,,,141219364,1,HIV infection
14248971,142489712,2,F,,20190906,20171204,20190910,EXP,,BG-MYLANLABS-2017M1075485,MYLAN,"YANCHEVA N, TEMELKOVA N, STRASHIMIROV D, GABARSKA I, TCHERVENYAKOVA T. ANTIRETROVIRAL THERAPY AND BONE HEALTH. ACTA MEDICA BULGARICA.. 2019;46:5-10",45,YR,,M,Y,,,20190910,,MD,BG,BG,EFAVIRENZ.,Osteoporosis,142489712,OT,,,,,,,,,142489712,1,HIV infection
14306973,143069735,5,F,,20190918,20171220,20190930,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20190930,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,143069735,OT,,,,,,,,,143069735,1,Bipolar disorder
14494652,144946526,6,F,,20190904,20180206,20190916,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190916,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,144946526,OT,,,,,,,,,144946526,1,HIV infection
14676686,146766862,2,F,,20190619,20180324,20190701,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-025144,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20190701,,OT,ZA,ZA,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,146766862,HO,,,146766862,1,20180214,,,,146766862,1,HIV infection
14682623,146826234,4,F,20180313,20190619,20180327,20190702,EXP,,ZA-AUROBINDO-AUR-APL-2018-015610,AUROBINDO,,,,,,Y,,,20190702,,OT,ZA,ZA,EFAVIRENZ.,Cardiac murmur;Maternal exposure during pregnancy,146826234,HO,,,146826234,1,20180214,,,,146826234,1,HIV infection
14705555,147055554,4,F,2005,20190729,20180402,20190805,EXP,,US-ASTRAZENECA-2018SE39858,ASTRAZENECA,,54,YR,,F,Y,67.6,KG,20190805,,,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Renal failure;Renal injury,147055554,OT,,,147055554,1,200201,201601,,,147055554,1,Gastrooesophageal reflux disease
14711217,147112177,7,F,200505,20190731,20180403,20190806,EXP,,US-PFIZER INC-2018133712,PFIZER,,,,,M,Y,69,KG,20190806,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Gastrooesophageal reflux disease;Renal injury,147112177,OT,,,147112177,1,200201,201601,,,147112177,1,Gastrooesophageal reflux disease
14723192,147231924,4,F,200505,20190731,20180405,20190814,EXP,,US-TAKEDA-2018TUS008588,TAKEDA,,,,,,Y,,,20190814,,OT,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Gastrooesophageal reflux disease;Renal injury,147231924,OT,,,147231924,1,200201,201601,,,147231924,1,Product used for unknown indication
14782075,147820752,2,F,,20180406,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035829,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myasthenia gravis,147820752,OT,,,,,,,,,147820752,1,HIV infection
14782122,147821222,2,F,,20180406,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035832,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Sarcoidosis,147821222,OT,,,,,,,,,147821222,1,HIV infection
14782138,147821382,2,F,,20180406,20180420,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-035835,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190722,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune thrombocytopenic purpura,147821382,OT,,,,,,,,,147821382,1,HIV infection
14942174,149421742,2,F,,20180514,20180528,20190913,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-048844,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190913,,OT,AU,ET,EFAVIRENZ.,Drug interaction;Hepatotoxicity,149421742,HO,,,,,,,,,149421742,1,Product used for unknown indication
15037588,150375883,3,F,20171227,20180823,20180620,20190712,EXP,,ZA-MYLANLABS-2018M1043162,MYLAN,,22,YR,,M,Y,42,KG,20190712,,MD,ZA,ZA,EFAVIRENZ.,Bundle branch block left;Chest pain;Incorrect product administration duration,150375883,LT,,,150375883,1,20170330,20171227,,,150375883,1,Pulmonary tuberculosis
15114149,151141498,8,F,20171006,20190827,20180706,20190910,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,,,,,Y,,,20190910,,OT,GB,GB,Efavirenz Film-coated Tablet,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151141498,OT,,,151141498,1,20171006,20180205,,,151141498,1,HIV infection
15118575,151185753,3,F,,20180625,20180709,20190815,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-059819,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190815,,OT,IT,IT,EFAVIRENZ.,Neurotoxicity;Toxicity to various agents,151185753,OT,,,,,,,,,151185753,1,HIV infection
15123625,1512362515,15,F,20180205,20190814,20180710,20190826,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190826,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362515,OT,,,1512362515,1,20171006,20180205,,,1512362515,1,HIV infection
15123626,1512362613,13,F,20180112,20190814,20180710,20190826,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190826,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362613,OT,,,1512362613,1,20171006,20180205,,,1512362613,1,Product used for unknown indication
15152012,151520127,7,F,,20190826,20180717,20190903,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063262,BRISTOL MYERS SQUIBB,,,,N,F,Y,,,20190903,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151520127,CA,,,151520127,1,20110301,20180601,,,151520127,1,Product used for unknown indication
15158165,151581657,7,F,20171006,20190814,20180718,20190828,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,,,,,Y,,,20190828,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,151581657,OT,,,151581657,1,20171006,20180205,,,151581657,1,HIV infection
15235019,152350195,5,F,,20190823,20180803,20190826,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002637",BOEHRINGER INGELHEIM,,,,N,,Y,,,20190827,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Spina bifida;Spinocerebellar disorder,152350195,DE,,,152350195,1,20050704,20050908,,,152350195,1,HIV infection
15248149,152481497,7,F,20060216,20190729,20180807,20190805,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,,,A,F,Y,56,KG,20190805,,MD,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,152481497,HO,,,152481497,1,20050620,20050908,,,152481497,1,HIV infection
15317962,153179623,3,F,20171006,20190819,20180824,20190826,EXP,,PHHY2018GB074559,SANDOZ,,,,,M,Y,,,20190826,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153179623,OT,,,153179623,4,20171006,20180205,,,153179623,1,Foetal exposure during pregnancy
15357909,153579093,3,F,20171006,20190819,20180906,20190826,EXP,,PHHY2018GB086977,SANDOZ,,43,YR,,F,Y,,,20190827,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,153579093,OT,,,153579093,3,20171006,20180205,,,153579093,1,Product used for unknown indication
15370793,153707932,2,F,20171006,20180910,20180911,20190820,EXP,,GB-TEVA-2018-GB-953327,TEVA,,,,,M,Y,,,20190820,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153707932,OT,,,153707932,1,20171006,20180205,,,153707932,1,Product used for unknown indication
15473109,154731098,8,F,,20190110,20181008,20190820,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092264,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20190820,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154731098,LT,,,,,,,,,154731098,1,Chronic hepatitis C
15488801,154888014,4,F,,20190910,20181011,20190920,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-090269,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20190920,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Intentional product use issue;Live birth;Maternal exposure during pregnancy;Premature rupture of membranes,154888014,OT,,,,,,,,,154888014,1,Antiretroviral therapy
15515252,155152524,4,F,,20190703,20181017,20190715,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078173,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190715,,OT,PT,PT,EFAVIRENZ.,Neuropsychiatric symptoms,155152524,OT,,,,,,,,,155152524,1,Chronic hepatitis C
15559787,155597874,4,F,,20190704,20181029,20190705,EXP,,PHHY2018PT113969,SANDOZ,,32,YR,,M,Y,,,20190706,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,155597874,OT,,,,,,,,,155597874,1,HIV infection
15573679,155736796,6,F,,20190912,20181101,20190916,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,,M,Y,,,20190916,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,155736796,OT,,,,,,,,,155736796,1,HIV infection
15580903,155809032,2,F,,20181023,20181105,20190717,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100299,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,,,20190717,,OT,UG,UG,EFAVIRENZ.,Asthenia;Coma;Condition aggravated;Decreased appetite;General physical health deterioration;Generalised tonic-clonic seizure;Hypotension;Hypoxia,155809032,HO,,,,,,,,,155809032,1,HIV infection
15580993,155809932,2,F,,20181023,20181105,20190717,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100312,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,,,20190717,,OT,UG,UG,EFAVIRENZ.,General physical health deterioration;Intracranial pressure increased,155809932,OT,,,,,,,,,155809932,1,HIV infection
15621334,156213342,2,F,2018,20190815,20181115,20190819,EXP,,UG-MYLANLABS-2018M1086709,MYLAN,,,,,M,Y,2.93,KG,20190819,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156213342,OT,,,156213342,1,20180417,,,,156213342,1,HIV infection
15622123,156221233,3,F,2018,20190823,20181115,20190828,EXP,,UG-MYLANLABS-2018M1086992,MYLAN,,,,N,M,Y,4.2,KG,20190828,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221233,CA,,,156221233,1,20180406,,,,156221233,1,HIV infection
15622136,156221364,4,F,2018,20190823,20181115,20190828,EXP,,UG-MYLANLABS-2018M1086990,MYLAN,,0,YR,,F,Y,3,KG,20190828,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221364,CA,,,156221364,1,20180412,,,,156221364,1,HIV infection
15626751,156267514,4,F,,20190918,20181116,20190924,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20190924,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,156267514,OT,,,,,,,,,156267514,1,HIV infection
15628175,156281752,2,F,2018,20190820,20181116,20190826,EXP,,UG-MYLANLABS-2018M1086989,MYLAN,,,,I,F,Y,,,20190826,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156281752,CA,,,156281752,1,20180607,,,,156281752,1,HIV infection
15629934,156299343,3,F,,20190815,20181117,20190820,EXP,,UG-MYLANLABS-2018M1086681,MYLAN,,,,,M,Y,2.8,KG,20190820,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156299343,OT,,,156299343,1,20180503,,,,156299343,1,HIV infection
15854101,158541013,3,F,20181127,20190903,20190122,20190904,EXP,FR-AFSSAPS-NC20190054,FR-ABBVIE-19S-056-2634604-00,ABBVIE,,52,YR,,M,Y,46,KG,20190904,,MD,FR,FR,EFAVIRENZ.,Muscular weakness;Paresis;Renal tubular disorder,158541013,LT,,,158541013,2,20180815,20181015,,,158541013,1,HIV infection
15962439,159624396,6,F,20181001,20190722,20190214,20190814,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2018GSK236781,VIIV,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20190814,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624396,OT,,,159624396,1,20170330,,,,159624396,1,HIV infection
15962440,159624406,6,F,20181001,20190722,20190214,20190814,EXP,,BW-GLAXOSMITHKLINE-BW2018GSK236781,GLAXOSMITHKLINE,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20190814,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624406,OT,,,159624406,1,20170330,,,,159624406,1,HIV infection
15964658,159646582,2,F,,20190829,20190215,20190912,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019020010,MACLEODS,,,,,,Y,,,20190912,,CN,US,UG,"Lamivudine, Efavirenz + Tenofovir",Foetal exposure during pregnancy;Foot deformity;Talipes,159646582,OT,,,159646582,1,20180521,,,,159646582,1,HIV infection
16020890,160208906,6,F,,20190910,20190301,20190924,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20190924,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160208906,OT,,,,,,,,,160208906,1,HIV infection
16022512,160225125,5,F,,20190909,20190301,20190923,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,,52,YR,,M,Y,,,20190923,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,160225125,CA,,,,,,,,,160225125,1,HIV infection
16064851,160648514,4,F,2017,20190903,20190312,20190910,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,71,YR,,M,Y,73.09,KG,20190910,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Cataract;Decreased appetite;Infection;Mobility decreased;Neoplasm;Neoplasm skin;Pain;Psoriasis;Psoriatic arthropathy;Skin discolouration;Subcutaneous abscess;Weight increased;Wound secretion,160648514,OT,,,160648514,1,20150504,201901,,,160648514,1,Psoriatic arthropathy
16070460,160704603,3,F,20110825,20190916,20190314,20190926,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018223044,VIIV,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35,YR,,F,Y,,,20190926,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704603,OT,,,,,,,,,160704603,1,HIV infection
16070467,160704673,3,F,20110825,20190916,20190314,20190926,EXP,,FR-GLAXOSMITHKLINE-FR2018223044,GLAXOSMITHKLINE,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35,YR,,F,Y,,,20190926,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704673,OT,,,,,,,,,160704673,1,HIV infection
16081150,160811502,2,F,,20190910,20190316,20190924,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,,,,M,Y,,,20190924,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811502,OT,,,,,,,,,160811502,1,Product used for unknown indication
16081152,160811522,2,F,,20190709,20190316,20190723,EXP,,CA-AUROBINDO-AUR-APL-2019-013775,AUROBINDO,,,,,,Y,,,20190723,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811522,HO,,,,,,,,,160811522,1,Product used for unknown indication
16110186,161101863,3,F,,20190813,20190325,20190917,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-025640,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190917,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,161101863,OT,,,,,,,,,161101863,1,Product used for unknown indication
16112768,161127683,3,F,20181128,20190613,20190325,20190710,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK218858,VIIV,,4,MON,,M,Y,,,20190710,,MD,UG,UG,EFAVIRENZ.,Dactylitis;Sickle cell anaemia,161127683,HO,,,161127683,1,20180522,201810,,,161127683,1,HIV infection
16147793,161477933,3,F,,20190712,20190402,20190722,EXP,,CA-PFIZER INC-2019136429,PFIZER,,54,YR,,M,Y,,,20190722,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,161477933,OT,,,,,,,,,161477933,1,Bipolar disorder
16158910,161589102,2,F,20110825,20190831,20190404,20190912,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-118425,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20190912,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,161589102,OT,,,,,,,,,161589102,1,HIV infection
16198926,161989262,2,F,,20190718,20190415,20190725,EXP,,FR-MYLANLABS-2019M1034886,MYLAN,,,,A,F,Y,,,20190725,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,161989262,OT,,,161989262,1,200308,200507,,,161989262,1,HIV infection
16231775,162317753,3,F,,20190820,20190424,20190824,EXP,,CA-ABBVIE-19S-028-2752397-00,ABBVIE,,52,YR,,M,Y,,,20190824,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,162317753,OT,,,,,,,,,162317753,1,HIV infection
16249617,162496178,8,F,,20190716,20190429,20190719,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019405",BOEHRINGER INGELHEIM,,,,N,,Y,,,20190719,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162496178,DE,,,162496178,1,20050704,20050908,,,162496178,1,HIV infection
16251297,162512974,4,F,20050813,20190826,20190429,20190827,EXP,,FR-GILEAD-2019-0404516,GILEAD,,,,N,,Y,,,20190827,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,162512974,OT,,,162512974,1,20050523,20050908,,,162512974,1,HIV infection
16261847,162618474,4,F,,20190925,20190501,20190930,EXP,,CA-GILEAD-2019-0405133,GILEAD,,,,I,,Y,,,20190930,,OT,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162618474,CA,,,,,,,,,162618474,1,HIV infection
16271062,162710625,5,F,,20190821,20190503,20190822,EXP,,FR-ABBVIE-19S-056-2763487-00,ABBVIE,,,,N,,Y,,,20190821,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,162710625,DE,,,162710625,1,20050908,20050908,,,162710625,1,Maternal exposure timing unspecified
16272000,162720002,2,F,,20190801,20190506,20190806,EXP,,FR-STRIDES ARCOLAB LIMITED-2019SP003754,STRIDES,,43,YR,,F,Y,,,20190806,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Hydrops foetalis,162720002,OT,,,162720002,2,20171006,,,,162720002,1,HIV infection
16284374,162843742,2,F,,20190424,20190508,20190722,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-042035,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20190722,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162843742,DE,,,162843742,1,20050513,20050908,,,162843742,1,Product used for unknown indication
16284485,162844854,4,F,,20190910,20190508,20190924,EXP,,CA-AUROBINDO-AUR-APL-2019-025238,AUROBINDO,,,,I,,Y,,,20190925,,OT,CA,CA,Tenofovir + efavirenz + emtricitabine,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162844854,CA,,,,,,,,,162844854,1,HIV infection
16295406,162954062,2,F,,20190715,20190509,20190726,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021165,MACLEODS,,,,,,Y,,,20190726,,OT,GB,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162954062,CA,,,162954062,1,20050704,20050908,,,162954062,1,Product used for unknown indication
16303467,163034673,3,F,,20190801,20190513,20190813,EXP,,GB-HETERO-HET2019GB00641,HETERO,,43,YR,,F,Y,,,20190813,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163034673,OT,,,163034673,1,20171006,,,,163034673,1,HIV infection
16309927,163099274,4,F,200101,20190703,20190514,20190710,EXP,,FR-MYLANLABS-2019M1044768,MYLAN,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI-GRADT E, GUILLOU-GUILLEMETTE HL, CHENNEBAULT JM.. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV-1 GROUP O.. AIDS. 2016;30 (16):2565-8",,,,F,Y,,,20190710,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,163099274,OT,,,,,,,,,163099274,1,HIV infection
16395888,163958882,2,F,20190224,20190703,20190605,20190704,EXP,,US-GILEAD-2019-0411957,GILEAD,,48,YR,A,M,Y,113,KG,20190704,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,163958882,DE,,,,,,,,,163958882,1,HIV infection
16410957,164109572,2,F,,20190529,20190610,20190823,EXP,,US-VIIV HEALTHCARE LIMITED-US2019AMR103087,VIIV,,,,,M,Y,,,20190823,,CN,US,US,EFAVIRENZ.,Blood creatinine increased;Proteinuria;Renal failure;Viraemia;Viral mutation identified,164109572,OT,,,,,,,,,164109572,1,HIV infection
16410974,164109742,2,F,,20190529,20190610,20190823,EXP,,US-GLAXOSMITHKLINE-US2019AMR103087,GLAXOSMITHKLINE,,,,,M,Y,,,20190823,,CN,US,US,EFAVIRENZ.,Blood creatinine increased;Proteinuria;Renal failure;Viraemia;Viral mutation identified,164109742,OT,,,,,,,,,164109742,1,HIV infection
16439329,164393292,2,F,,20190905,20190617,20190912,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106102,VIIV,,52,YR,,M,Y,,,20190912,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,164393292,OT,,,,,,,,,164393292,1,HIV infection
16439340,164393402,2,F,,20190905,20190617,20190912,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106102,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20190912,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,164393402,CA,,,,,,,,,164393402,1,HIV infection
16446046,164460463,3,F,20190119,20190916,20190618,20190917,EXP,,ZA-GILEAD-2019-0413802,GILEAD,,42,YR,A,F,Y,,,20190917,,OT,ZA,ZA,SUSTIVA,Abortion spontaneous;Maternal exposure during pregnancy,164460463,OT,,,164460463,1,20140501,,,,164460463,1,Product used for unknown indication
16446422,164464222,2,F,201805,20190611,20190618,20190731,EXP,,US-GILEAD-2019-0413810,GILEAD,,54,YR,A,M,Y,111.3,KG,20190731,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Depression;Mental disorder;Substance abuse,164464222,OT,,,164464222,2,1999,,,,164464222,1,HIV infection
16457895,164578953,3,F,20181123,20190712,20190620,20190718,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018GSK214194,VIIV,,19,YR,,F,Y,44.4,KG,20190718,,MD,ZW,ZW,EFAVIRENZ.,Exposure during pregnancy;Live birth;Pneumonia,164578953,HO,,,164578953,1,20170321,20181123,,,164578953,1,HIV infection
16457897,164578973,3,F,20181123,20190712,20190620,20190718,EXP,,ZW-GLAXOSMITHKLINE-ZW2018GSK214194,GLAXOSMITHKLINE,,19,YR,,F,Y,44.4,KG,20190718,,MD,ZW,ZW,EFAVIRENZ.,Exposure during pregnancy;Live birth;Pneumonia,164578973,HO,,,164578973,1,20170321,20181123,,,164578973,1,HIV infection
16467469,164674692,2,F,,20190907,20190624,20190921,EXP,,GB-AUROBINDO-AUR-APL-2019-034453,AUROBINDO,,,,A,F,Y,,,20190921,,OT,GB,GB,EFAVIRENZ.,Alanine aminotransferase increased;C-reactive protein increased;Exposure during pregnancy;Medication error;Pyrexia,164674692,OT,,,,,,,,,164674692,1,Antiretroviral therapy
16470789,164707893,3,F,,20190924,20190624,20190927,EXP,,UG-MYLANLABS-2019M1058216,MYLAN,,,,,F,Y,3.7,KG,20190927,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Congenital skin dimples;Congenital umbilical hernia;Foetal exposure during pregnancy,164707893,CA,,,164707893,1,20170721,,,,164707893,1,HIV infection
16474063,164740632,2,F,,20190703,20190625,20190708,EXP,,IN-SA-2019SA171771,SANOFI AVENTIS,,38,YR,A,F,Y,,,20190708,,OT,IN,IN,EFAVIRENZ.,Blood bilirubin increased;Crepitations;Dyspnoea;HIV infection;Haemophagocytic lymphohistiocytosis;Hepatosplenomegaly;Hyperbilirubinaemia;Hypochromic anaemia;Jaundice;Pancytopenia;Pneumonia;Pyrexia;Treatment failure,164740632,LT,,,,,,,,,164740632,1,Haemophagocytic lymphohistiocytosis
16474440,164744403,3,F,20151123,20190920,20190625,20190925,EXP,,BR-GILEAD-2019-0414876,GILEAD,,26,YR,A,F,Y,,,20190925,,MD,BR,BR,EFAVIRENZ.,Hepatitis fulminant,164744403,OT,,,164744403,1,20150831,20160107,,,164744403,1,HIV infection
16475912,164759122,2,F,1996,20190716,20190625,20190722,EXP,,IT-MYLANLABS-2019M1058328,MYLAN,"LANZAFAME M, LATTUADA E, RIZZARDO S, PIACENTINI D, CHIESI S, MAZZI R.. DOLUTEGRAVIR MONOTHERAPY^S VIROLOGICAL EFFICACY IN A HIGHLY TREATMENT-EXPERIENCED PATIENT.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019",74,YR,,F,Y,,,20190722,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Genotype drug resistance test negative;Treatment failure;Treatment noncompliance;Virologic failure,164759122,OT,,,164759122,1,2002,201502,,,164759122,1,HIV infection
16482251,164822513,3,F,20190122,20190919,20190627,20190923,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-060326,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20190923,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164822513,OT,,,164822513,1,20140501,,,,164822513,1,HIV infection
16494843,164948434,4,F,201906,20190912,20190628,20190912,EXP,,US-GILEAD-2019-0415427,GILEAD,,64,YR,A,M,Y,81.25,KG,20190912,,CN,US,US,SUSTIVA,Amnesia;Anal cancer;Anxiety;Arthralgia;Colorectal cancer;Diarrhoea;Disturbance in attention;Gait disturbance;Gastrointestinal disorder;HIV-associated neurocognitive disorder;Insomnia;Laboratory test abnormal;Lipids abnormal;Neuropathy peripheral;Nightmare;Osteopenia;Pain in extremity;Stevens-Johnson syndrome;Tinnitus,164948434,OT,,,164948434,7,201903,,,,164948434,1,HIV infection
16499274,164992741,1,I,,20190618,20190701,20190701,EXP,,ZA-CIPLA LTD.-2019ZA04631,CIPLA,,,,,,Y,,,20190701,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Corneal opacity congenital;Foetal exposure during pregnancy,164992741,CA,,,,,,,,,,,
16499390,164993901,1,I,,20190618,20190701,20190701,EXP,,ZA-CIPLA LTD.-2019ZA04630,CIPLA,,,,,,Y,,,20190701,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Exposure during pregnancy;No adverse event,164993901,OT,,,,,,,,,164993901,1,HIV infection
16499608,164996081,1,I,,20190625,20190701,20190701,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116833,VIIV,,,,,M,Y,62,KG,20190701,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,164996081,OT,,,164996081,2,201411,,,,164996081,1,HIV infection
16500823,165008231,1,I,2013,20190626,20190701,20190701,EXP,,US-GILEAD-2019-0415961,GILEAD,,45,YR,A,M,Y,,,20190701,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,"Hallucination, visual;Intentional dose omission",165008231,OT,,,165008231,1,2013,2014,,,165008231,1,HIV infection
16507810,165078101,1,I,2002,20190624,20190701,20190701,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116835,VIIV,,,,E,M,Y,,,20190701,,MD,DE,DE,EFAVIRENZ.;SUSTIVA,Aortic stenosis;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Musculoskeletal pain;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078101,HO,,,165078101,1,199702,201510,,,165078101,1,HIV infection
16507857,165078571,1,I,2002,20190624,20190701,20190701,EXP,,DE-GLAXOSMITHKLINE-DE2019GSK116835,GLAXOSMITHKLINE,,,,E,M,Y,,,20190701,,MD,DE,DE,EFAVIRENZ.;SUSTIVA,Aortic stenosis;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Musculoskeletal pain;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078571,HO,,,165078571,1,199702,201510,,,165078571,1,HIV infection
16514432,165144324,4,F,,20190720,20190702,20190803,EXP,,DK-AUROBINDO-AUR-APL-2019-037048,AUROBINDO,,,,,,Y,,,20190803,,MD,DK,DK,EFAVIRENZ.,Arthralgia;Atypical mycobacterial infection;Bursitis;Bursitis infective;Depression;Immune reconstitution inflammatory syndrome;Post-traumatic stress disorder;Scar,165144324,OT,,,,,,,,,165144324,1,HIV infection
16519280,165192801,1,I,,20190621,20190702,20190702,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-061353,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190702,,CN,US,US,SUSTIVA,Depression;Suicidal ideation,165192801,OT,,,165192801,1,1999,2010,,,165192801,1,HIV infection
16524746,165247461,1,I,20180219,20190619,20190703,20190703,EXP,,ZA-MYLANLABS-2019M1061790,MYLAN,,35,YR,,F,Y,,,20190703,,OT,ZA,ZA,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,165247461,HO,,,165247461,1,20180214,,,,165247461,1,HIV infection
16526680,165266801,1,I,,20190702,20190704,20190704,EXP,GB-MHRA-EYC 00202394,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-002090",BOEHRINGER INGELHEIM,,,,,M,Y,,,20190704,,OT,GB,GB,EFAVIRENZ.,Pulmonary embolism,165266801,HO,,,,,,,,,165266801,1,Product used for unknown indication
16527750,165277501,1,I,,20190626,20190703,20190703,EXP,,PHHY2019LK150195,NOVARTIS,,46,YR,,F,Y,,,20190703,,OT,LK,LK,EFAVIRENZ.,Decreased appetite;Product use in unapproved indication;Pulmonary tuberculosis;Pyrexia;Subcutaneous abscess;Weight decreased,165277501,OT,,,,,,,,,165277501,1,Tuberculoid leprosy
16530603,165306031,1,I,,20190628,20190704,20190704,EXP,,UG-CIPLA LTD.-2019UG04802,CIPLA,,,,,,Y,,,20190704,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Burning sensation;Chest pain;Hypoaesthesia,165306031,DS,,,165306031,1,20190105,20190114,,,165306031,1,Product used for unknown indication
16531183,165311831,1,I,,20190701,20190704,20190704,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019119847,VIIV,,38,YR,,F,Y,,,20190704,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165311831,OT,,,,,,,,,165311831,1,HIV infection
16531187,165311871,1,I,,20190701,20190704,20190704,EXP,,IN-GLAXOSMITHKLINE-IN2019119847,GLAXOSMITHKLINE,,38,YR,,F,Y,,,20190704,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165311871,OT,,,,,,,,,165311871,1,HIV infection
16536330,165363301,1,I,,20190625,20190705,20190705,EXP,,US-CIPLA LTD.-2019US04767,CIPLA,"KARASINSKI A, RAZA A, AGGARWAL S. AN AILING KIDNEY WITH A CHANGE OF HAART AN INTERESTING CASE OF RAPIDLY PROGRESSIVE HIV ASSOCIATED IMMUNE COMPLEX KIDNEY DISEASE (HIVICK) AFTER A CHANGE IN HIV THERAPY. AMERICAN JOURNAL OF KIDNEY DISEASES. 2018;71(4):552 TO 553",,,,,Y,,,20190705,,OT,US,US,EFAVIRENZ.,Renal failure,165363301,OT,,,,,,,,,165363301,1,HIV infection
16536490,165364902,2,F,20190325,20190705,20190706,20190711,EXP,,BR-HETERO-HET2019BR00902,HETERO,,0,DY,,M,Y,2.78,KG,20190711,,OT,BR,BR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO (EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE),Ankyloglossia congenital;Foetal exposure during pregnancy;Premature baby,165364902,CA,,,165364902,1,20181018,20181024,,,165364902,1,HIV infection
16536496,165364962,2,F,20190325,20190705,20190706,20190711,EXP,,BR-HETERO-HET2019BR00903,HETERO,,24,YR,,F,Y,,,20190711,,OT,BR,BR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Exposure during pregnancy;Premature delivery,165364962,OT,,,165364962,1,20181018,20181024,,,165364962,1,HIV infection
16536587,165365873,3,F,20060216,20190821,20190706,20190905,EXP,,FR-AUROBINDO-AUR-APL-2019-038824,AUROBINDO,,,,,,Y,,,20190905,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,165365873,CA,,,165365873,1,20050704,20050908,,,165365873,1,HIV infection
16537810,165378101,1,I,,20190627,20190708,20190708,EXP,,IN-CIPLA LTD.-2019IN04816,CIPLA,"FAZAL F, GUPTA N, RAMU SK, NAYAN N, VIKRAM NK, RAY A.. HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION: TO TREAT OR NOT TO TREAT. PAN AFRICAN MEDICAL JOURNAL. 2019;32:105",,,,,Y,,,20190708,,OT,IN,IN,EFAVIRENZ.,Virologic failure,165378101,OT,,,,,,,,,165378101,1,HIV infection
16539046,165390461,1,I,,20190703,20190708,20190708,EXP,,US-GILEAD-2019-0416714,GILEAD,,,,A,F,Y,,,20190708,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Coronary arterial stent insertion,165390461,OT,,,165390461,1,2019,2019,,,165390461,1,HIV infection
16541950,165419501,1,I,201802,20190705,20190708,20190708,EXP,,US-GILEAD-2019-0416980,GILEAD,,54,YR,A,M,Y,,,20190708,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness;Meningitis;Product use issue,165419501,OT,,,,,,,,,165419501,1,HIV infection
16542961,165429611,1,I,,20190625,20190709,20190709,EXP,,CA-AUROBINDO-AUR-APL-2019-037761,AUROBINDO,,,,,,Y,,,20190709,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165429611,OT,,,,,,,,,165429611,1,Product used for unknown indication
16543052,165430521,1,I,,20190625,20190709,20190709,EXP,,CA-AUROBINDO-AUR-APL-2019-037770,AUROBINDO,,,,,,Y,,,20190709,,OT,CA,CA,SUSTIVA,Drug ineffective;Drug interaction,165430521,OT,,,,,,,,,165430521,1,Product used for unknown indication
16543299,165432991,1,I,,20190626,20190709,20190709,EXP,,IT-MACLEODS PHARMACEUTICALS US LTD-MAC2019021963,MACLEODS,,,,,,Y,,,20190709,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Retroviral infection,165432991,OT,,,,,,,,,165432991,1,HIV infection
16544746,165447464,4,F,2019,20190821,20190709,20190903,EXP,,ZA-JNJFOC-20190630148,JOHNSON AND JOHNSON,,28,YR,,M,Y,62,KG,20190903,,MD,ZA,ZA,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Cor pulmonale acute;Drug-induced liver injury;Hyponatraemia;Pneumothorax;Respiratory distress,165447464,HO,,,165447464,1,20190311,20190528,,,165447464,1,Tuberculosis
16549468,165494681,1,I,,20190625,20190710,20190710,EXP,,CA-AUROBINDO-AUR-APL-2019-037814,AUROBINDO,,,,,,Y,,,20190710,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165494681,OT,,,,,,,,,165494681,1,Product used for unknown indication
16549483,165494831,1,I,,20190625,20190710,20190710,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,,,,,Y,,,20190710,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165494831,OT,,,,,,,,,165494831,1,Product used for unknown indication
16549523,165495231,1,I,,20190625,20190710,20190710,EXP,,CA-AUROBINDO-AUR-APL-2019-038401,AUROBINDO,,,,,,Y,,,20190710,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165495231,OT,,,,,,,,,165495231,1,Product used for unknown indication
16549598,165495981,1,I,,20190625,20190710,20190710,EXP,,CA-AUROBINDO-AUR-APL-2019-039459,AUROBINDO,,,,,,Y,,,20190710,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165495981,OT,,,,,,,,,165495981,1,Product used for unknown indication
16550921,165509213,3,F,,20190912,20190710,20190917,EXP,,CA-TEVA-2019-CA-1073146,TEVA,,54,YR,,M,Y,,,20190917,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,165509213,OT,,,,,,,,,165509213,1,Bipolar disorder
16553196,165531961,1,I,,20190708,20190710,20190710,EXP,,US-GILEAD-2019-0417343,GILEAD,,,,A,M,Y,,,20190710,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal injury,165531961,OT,,,,,,,,,165531961,1,HIV infection
16557080,165570801,1,I,,20190702,20190711,20190711,EXP,,CH-GLAXOSMITHKLINE-ZW2019GSK121329,GLAXOSMITHKLINE,"CHIMBETETE C, CHIRIMUTA L, PASCOE M, KEISER O.. A CASE REPORT OF UNTREATABLE HIV INFECTION IN HARARE, ZIMBABWE. S AFR J HIV MED. 2019;20(1):A885, DOI: HTTPS://DOI.ORG/ 10",17,YR,,F,Y,,,20190711,,MD,CH,ZW,EFAVIRENZ.,Drug resistance;Pathogen resistance;Pulmonary tuberculosis;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight decreased,165570801,OT,,,,,,,,,165570801,1,HIV infection
16557082,165570821,1,I,,20190703,20190711,20190711,EXP,,IN-GLAXOSMITHKLINE-IN2019GSK121369,GLAXOSMITHKLINE,,51,YR,,F,Y,,,20190711,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood HIV RNA increased;Blood bilirubin increased;Central nervous system immune reconstitution inflammatory response;Central nervous system lesion;Cough;Disseminated tuberculosis;Drug-induced liver injury;Focal dyscognitive seizures;General physical health deterioration;Immune reconstitution inflammatory syndrome associated tuberculosis;Jaundice;Lymphadenopathy;Muscle abscess;Night sweats;Partial seizures;Portal vein occlusion;Pruritus generalised;Pulmonary tuberculosis;Pyrexia;Swelling;Tuberculoma of central nervous system;Weight decreased,165570821,OT,,,165570821,3,20180508,20180508,,,165570821,1,Antiretroviral therapy
16557088,165570881,1,I,,20190702,20190711,20190711,EXP,,CH-VIIV HEALTHCARE LIMITED-ZW2019GSK121329,VIIV,"CHIMBETETE C, CHIRIMUTA L, PASCOE M, KEISER O.. A CASE REPORT OF UNTREATABLE HIV INFECTION IN HARARE, ZIMBABWE. S AFR J HIV MED. 2019;20(1):A885, DOI: HTTPS://DOI.ORG/ 10",17,YR,,F,Y,,,20190711,,MD,CH,ZW,EFAVIRENZ.,Drug resistance;Pathogen resistance;Pulmonary tuberculosis;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight decreased,165570881,OT,,,,,,,,,165570881,1,HIV infection
16557089,165570891,1,I,,20190703,20190711,20190711,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019GSK121369,VIIV,,51,YR,,F,Y,,,20190711,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood HIV RNA increased;Blood bilirubin increased;Central nervous system immune reconstitution inflammatory response;Central nervous system lesion;Cough;Disseminated tuberculosis;Drug-induced liver injury;Focal dyscognitive seizures;General physical health deterioration;Immune reconstitution inflammatory syndrome associated tuberculosis;Jaundice;Lymphadenopathy;Muscle abscess;Night sweats;Partial seizures;Portal vein occlusion;Pruritus generalised;Pulmonary tuberculosis;Pyrexia;Swelling;Tuberculoma of central nervous system;Weight decreased,165570891,OT,,,165570891,3,20180508,20180508,,,165570891,1,Antiretroviral therapy
16559338,165593381,1,I,,20190708,20190711,20190711,EXP,,CH-GILEAD-2019-0417596,GILEAD,"MALIKOVA J, ZINGG T, FINGERHUT R, SLUKA S, GROSSL M, BRIXIUS-ANDERKO S, BERNHARDT R, MCDOUGALL J, PANDEY AV, FLUCK CE. HIV DRUG EFAVIRENZ INHIBITS CYP21A2 ACTIVITY WITH POSSIBLE CLINICAL IMPLICATIONS. HORM RES PAEDIATR.. 2019;1-9:UNK. DOI:10.1159/000500522",,,N,F,Y,,,20190711,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Adrenal insufficiency neonatal;Foetal exposure during pregnancy,165593381,OT,,,,,,,,,165593381,1,HIV infection
16559365,165593652,2,F,,20190411,20190711,20190716,PER,,US-GILEAD-2019-0417804,GILEAD,,34,YR,A,M,Y,,,20190716,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nausea,,,,,165593652,1,201902,,,,165593652,1,HIV infection
16559366,165593662,2,F,201801,20190411,20190711,20190716,PER,,US-GILEAD-2019-0417806,GILEAD,,35,YR,A,,Y,,,20190716,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety;Dizziness;Fear;Rash,,,,,165593662,1,201801,,,,165593662,1,HIV infection
16559560,165595601,1,I,,20190708,20190711,20190711,EXP,,CH-GILEAD-2019-0417593,GILEAD,"MALIKOVA J, ZINGG T, FINGERHUT R, SLUKA S, GROSSL M, BRIXIUS-ANDERKO S, BERNHARDT R, MCDOUGALL J, PANDEY AV, FLUCK CE. HIV DRUG EFAVIRENZ INHIBITS CYP21A2 ACTIVITY WITH POSSIBLE CLINICAL IMPLICATIONS. HORM RES PAEDIATR.. 2019;1-9:UNK. DOI:10.1159/000500522",,,,F,Y,,,20190711,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature baby,165595601,OT,,,,,,,,,165595601,1,HIV infection
16559676,165596761,1,I,200808,20190704,20190711,20190711,EXP,,DE-SA-2019SA182823,SANOFI AVENTIS,,44,YR,A,M,Y,,,20190711,,OT,DE,DE,EFAVIRENZ.,Acute hepatic failure;Drug resistance;Hepatic function abnormal;Hepatitis B,165596761,OT,,,165596761,1,200209,2008,,,165596761,1,Antiretroviral therapy
16567899,165678991,1,I,,20190709,20190712,20190712,EXP,,GB-MYLANLABS-2019M1064898,MYLAN,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22,YR,,F,Y,,,20190712,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,165678991,OT,,,,,,,,,165678991,1,HIV infection
16568054,165680541,1,I,2012,20190705,20190712,20190712,EXP,,AT-GLAXOSMITHKLINE-AT2019GSK123941,GLAXOSMITHKLINE,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20190712,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,165680541,OT,,,165680541,1,20031107,20040423,,,165680541,1,Antiretroviral therapy
16568056,165680561,1,I,2012,20190705,20190712,20190712,EXP,,AT-VIIV HEALTHCARE LIMITED-AT2019GSK123941,VIIV,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20190712,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,165680561,OT,,,165680561,1,20031107,20040423,,,165680561,1,Antiretroviral therapy
16568467,165684671,1,I,,20190711,20190712,20190712,EXP,,US-GILEAD-2019-0418150,GILEAD,,,,,M,Y,,,20190712,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,165684671,DE,,,,,,,,,165684671,1,HIV infection
16571857,165718571,1,I,,20190709,20190715,20190715,EXP,,US-SA-2019SA186044,SANOFI AVENTIS,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K, ET AL.. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN FORUM INFECT DIS.. 2018;5(10):UNKNOWN",30,YR,A,F,Y,,,20190715,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Abdominal discomfort;Castleman's disease;Clostridium difficile colitis;Diarrhoea;Headache;Herpes virus infection;Immune reconstitution inflammatory syndrome associated tuberculosis;Kaposi's sarcoma;Lymph node abscess;Lymphadenopathy;Malaise;Nausea;Pyrexia;Unmasking of previously unidentified disease,165718571,OT,,,,,,,,,165718571,1,Tuberculosis
16572685,165726851,1,I,20060719,20190709,20190715,20190715,EXP,FR-EMA-20130709-MMEVHUMANWT-104720368,FR-MYLANLABS-2019M1064851,MYLAN,,41,YR,,F,Y,,,20190715,,MD,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,165726851,HO,,,165726851,1,20060717,20060721,,,165726851,1,Depression
16572757,165727571,1,I,,20190703,20190715,20190715,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-066000,BRISTOL MYERS SQUIBB,,71,YR,,M,Y,62,KG,20190715,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,165727571,OT,,,165727571,2,201411,,,,165727571,1,HIV infection
16574735,165747351,1,I,,20190708,20190715,20190715,EXP,,FR-BAUSCH-BL-2019-020256,BAUSCH AND LOMB,"ROUVE N, TELMON N, FRANCHITTO N, SCHMITT L, ROUGE D, LAPEYRE-MESTRE M, BAGHERI H, PATHAK A, MONTASTRUC J. PRESCRIBED DRUGS AND VIOLENCE: A CASE/NONCASE STUDY IN THE FRENCH PHARMACOVIGILANCE DATABASE. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2011;67(11):1189-1198. DOI:10.1007/S00228-011-1067-7",37,YR,,M,Y,,,20190715,,OT,FR,FR,EFAVIRENZ.,Aggression;Depression;Insomnia,165747351,OT,,,,,,,,,165747351,1,Product used for unknown indication
16576425,165764251,1,I,,20190214,20190716,20190716,EXP,,CA-AUROBINDO-AUR-APL-2019-010654,AUROBINDO,,,,,,Y,,,20190716,,OT,CA,CA,EFAVIRENZ.,Drug interaction;Drug level decreased;Transaminases increased,165764251,OT,,,,,,,,,165764251,1,HIV infection
16576907,165769071,1,I,,20190715,20190716,20190716,EXP,,US-GILEAD-2019-0418414,GILEAD,,,,A,M,Y,,,20190716,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,165769071,OT,,,,,,,,,165769071,1,HIV infection
16580930,165809301,1,I,201901,20190627,20190716,20190716,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR117290,VIIV,,,,,M,Y,,,20190716,,MD,BR,BR,EFAVIRENZ.,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint swelling;Neurosyphilis;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal manipulation;White blood cell disorder;Wound secretion,165809301,OT,,,165809301,3,201811,,,,165809301,1,HIV infection
16580959,165809591,1,I,201901,20190627,20190716,20190716,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR117290,GLAXOSMITHKLINE,,,,,M,Y,,,20190716,,MD,BR,BR,EFAVIRENZ.,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint swelling;Neurosyphilis;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal manipulation;White blood cell disorder;Wound secretion,165809591,OT,,,165809591,3,201811,,,,165809591,1,HIV infection
16582236,165822361,1,I,,20190702,20190717,20190717,EXP,,CA-AUROBINDO-AUR-APL-2019-039430,AUROBINDO,,,,,,Y,,,20190717,,OT,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,165822361,OT,,,,,,,,,165822361,1,HIV infection
16583290,165832901,1,I,,20190702,20190717,20190717,EXP,,CA-AUROBINDO-AUR-APL-2019-039499,AUROBINDO,,,,,,Y,,,20190717,,OT,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,165832901,OT,,,,,,,,,165832901,1,HIV infection
16583628,165836281,1,I,,20181126,20190717,20190717,EXP,,PT-AUROBINDO-AUR-APL-2018-058733,AUROBINDO,,,,,,Y,,,20190717,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis;Transaminases increased,165836281,LT,,,,,,,,,165836281,1,Product used for unknown indication
16588204,165882042,2,F,,20190814,20190717,20190815,EXP,,CA-GILEAD-2019-0418318,GILEAD,,,,N,,Y,,,20190815,,OT,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,165882042,CA,,,,,,,,,165882042,1,Prophylaxis against HIV infection
16588924,165889241,1,I,,20190703,20190718,20190718,EXP,,DE-AUROBINDO-AUR-APL-2019-040974,AUROBINDO,,,,,,Y,,,20190718,,MD,DE,DE,EFAVIRENZ.,Anaemia;Anal cancer;Sleep disorder,165889241,OT,,,165889241,2,201411,,,,165889241,1,HIV infection
16589219,165892191,1,I,,20190710,20190718,20190718,EXP,,IR-GLAXOSMITHKLINE-IR2019GSK126579,GLAXOSMITHKLINE,,,,A,M,Y,,,20190718,,OT,IR,IR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,165892191,OT,,,,,,,,,165892191,1,HIV infection
16589222,165892221,1,I,,20190710,20190718,20190718,EXP,,IR-VIIV HEALTHCARE LIMITED-IR2019GSK126579,VIIV,,,,A,M,Y,,,20190718,,OT,IR,IR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,165892221,OT,,,,,,,,,165892221,1,HIV infection
16589425,165894251,1,I,,20190703,20190718,20190718,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-070104,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20190718,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,165894251,OT,,,,,,,,,165894251,1,Product used for unknown indication
16589426,165894261,1,I,,20190703,20190718,20190718,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-066338,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20190718,,CN,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,165894261,OT,,,,,,,,,165894261,1,Product used for unknown indication
16590194,165901943,3,F,,20190912,20190718,20190916,EXP,,CA-TEVA-2018-CA-968075,TEVA,,44,YR,,M,Y,,,20190916,,OT,CA,CA,SUSTIVA,Anxiety,165901943,HO,,,,,,,,,165901943,1,HIV infection
16593072,165930723,3,F,,20190912,20190718,20190916,EXP,,CA-TEVA-2019-CA-1079149,TEVA,,,,,M,Y,,,20190916,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165930723,OT,,,,,,,,,165930723,1,HIV infection
16593140,165931401,1,I,,20190711,20190718,20190718,EXP,,CA-TEVA-2019-CA-1079153,TEVA,,,,,M,Y,,,20190718,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,165931401,OT,,,,,,,,,165931401,1,Product used for unknown indication
16594484,165944841,1,I,,20190711,20190718,20190718,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK130506,GLAXOSMITHKLINE,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",36,YR,,F,Y,,,20190718,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165944841,HO,,,,,,,,,165944841,1,HIV infection
16594488,165944881,1,I,,20190711,20190718,20190718,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK130506,VIIV,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",36,YR,,F,Y,,,20190718,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165944881,OT,,,,,,,,,165944881,1,HIV infection
16594631,165946311,1,I,,20190716,20190718,20190718,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-070971,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190718,,CN,US,US,SUSTIVA,Arthritis;Bone density abnormal;Osteoporosis,,,,,165946311,1,2003,,,,165946311,1,Product used for unknown indication
16594834,165948341,1,I,20190701,20190718,20190718,20190718,EXP,,US-GILEAD-2019-0418990,GILEAD,,58,YR,A,M,Y,,,20190718,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Oral candidiasis,165948341,DS,,,165948341,1,2015,,,,165948341,1,HIV infection
16596947,165969471,1,I,,20190711,20190719,20190719,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK130512,GLAXOSMITHKLINE,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",37,YR,,F,Y,,,20190719,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165969471,OT,,,,,,,,,165969471,1,HIV infection
16596948,165969481,1,I,,20190711,20190719,20190719,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK130512,VIIV,"CHEN S, GUI XE, CAO Q, ROUTY JP. CLINICAL OUTCOME AFTER LIPECTOMY IN THE MANAGEMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DORSOCERVICAL FAT ACCUMULATION: AN OBSERVATIONAL COHORT STUDY. MEDICINE. 2019;98 (25):DOI.ORG/10.1097/MD.00000000000",37,YR,,F,Y,,,20190719,,OT,CN,CN,EFAVIRENZ.,Dyslipidaemia;Fat tissue increased;Lipodystrophy acquired;Mobility decreased,165969481,OT,,,,,,,,,165969481,1,HIV infection
16598661,165986611,1,I,,20190709,20190719,20190719,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-068791,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190719,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,165986611,OT,,,,,,,,,165986611,1,HIV infection
16599716,165997161,1,I,,20190711,20190719,20190719,EXP,,CA-TEVA-2019-CA-1078848,TEVA,,44,YR,,M,Y,,,20190719,,OT,CA,CA,SUSTIVA,Anxiety,165997161,HO,,,,,,,,,165997161,1,HIV infection
16601723,166017232,2,F,,20190814,20190719,20190819,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019129907,VIIV,,,,N,,Y,,,20190819,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,166017232,CA,,,,,,,,,166017232,1,HIV infection
16601744,166017442,2,F,,20190814,20190719,20190819,EXP,,CA-GLAXOSMITHKLINE-CA2019129907,GLAXOSMITHKLINE,,,,N,,Y,,,20190819,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,166017442,CA,,,,,,,,,166017442,1,HIV infection
16601814,166018141,1,I,,20190708,20190719,20190719,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-068158,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,,,20190719,,MD,RO,RO,EFAVIRENZ.,Lipodystrophy acquired,166018141,OT,,,,,,,,,166018141,1,Product used for unknown indication
16618592,166185921,1,I,,20190718,20190723,20190723,EXP,,PT-MYLANLABS-2019M1069126,MYLAN,,59,YR,,M,Y,,,20190723,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,166185921,DE,,,,,,,,,166185921,1,HIV test positive
16623814,166238141,1,I,,20190709,20190724,20190724,EXP,,CA-AUROBINDO-AUR-APL-2019-042064,AUROBINDO,,,,,,Y,,,20190724,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,166238141,OT,,,,,,,,,166238141,1,Bipolar disorder
16624680,166246801,1,I,,20190717,20190724,20190724,EXP,,OM-BAUSCH-BL-2019-020899,BAUSCH AND LOMB,"BALUSHI A, KHAMIS F, KLAASSEN C, GANGNEUX J, VAN HELLEMOND J, PETERSEN E. DOUBLE INFECTION WITH LEISHMANIA TROPICA AND L. MAJOR IN AN HIV PATIENT CONTROLLED WITH HIGH DOSES OF AMPHOTERICIN B. OPEN FORUM INFECTIOUS DISEASES. 2018 DEC 07;1-3. DOI:10.1093/OFID/OFY323",40,YR,,M,Y,,,20190724,,MD,OM,OM,EFAVIRENZ.,Therapy non-responder;Treatment noncompliance,166246801,OT,,,166246801,2,2010,,,,166246801,1,Chronic hepatitis C
16628927,166289271,1,I,,20190716,20190725,20190725,EXP,,US-MYLANLABS-2019M1068635,MYLAN,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K, ET AL. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS 2018;5:NO. 10.",30,YR,,F,Y,,,20190725,,MD,US,US,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Castleman's disease;Immune reconstitution inflammatory syndrome associated tuberculosis;Lymph node abscess;Paradoxical drug reaction,166289271,OT,,,,,,,,,166289271,1,HIV infection
16633800,166338001,1,I,,20130212,20190725,20190725,EXP,,DK-GILEAD-2013-0069943,GILEAD,"LETH S, JENSEN-FANGEL S.. INFRAPATELLAR BURSITIS WITH MYCOBACTERIUM MALMOENSE RELATED TO IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-POSITIVE PATIENT. BMJ CASE REPORTS. 2012;10.1136:1-4. DOI:10.1136/BCR-2012-007459",39,YR,A,M,Y,,,20190725,,MD,DK,DK,EFAVIRENZ.,Arthralgia;Atypical mycobacterial infection;Bursitis;Bursitis infective;Immune reconstitution inflammatory syndrome;Scar,166338001,OT,,,,,,,,,166338001,1,HIV infection
16634649,166346491,1,I,20181001,20190715,20190726,20190726,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022219,MACLEODS,,,,,,Y,,,20190726,,OT,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,166346491,OT,,,,,,,,,166346491,1,HIV infection
16635444,166354441,1,I,,20190715,20190726,20190726,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022220,MACLEODS,,,,,,Y,,,20190726,,OT,US,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele,166354441,CA,,,,,,,,,166354441,1,Product used for unknown indication
16635462,166354621,1,I,20190613,20190712,20190726,20190726,EXP,,MM-AUROBINDO-AUR-APL-2019-042301,AUROBINDO,,,,,,Y,,,20190726,,OT,MM,MM,Tenofovir + Lamivudine + Efavirenz,Toxic optic neuropathy,166354621,OT,,,166354621,1,20181130,20190614,,,166354621,1,Tuberculosis
16635502,166355021,1,I,,20190719,20190726,20190726,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-071705,BRISTOL MYERS SQUIBB,,,,,F,Y,131.54,KG,20190726,,CN,US,US,SUSTIVA,Hypothyroidism;Inappropriate schedule of product administration;Weight increased,,,,,,,,,,,166355021,1,Cerebrovascular accident prophylaxis
16636329,166363291,1,I,20050813,20190715,20190726,20190726,EXP,,FR-PRINSTON PHARMACEUTICAL INC.-2019PRN00704,PRINSTON PHARMACEUTICAL,,25,YR,,F,Y,,,20190725,,CN,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Brain herniation;Exposure during pregnancy;Spina bifida,166363291,CA,,,166363291,1,20050704,20050908,,,166363291,1,HIV infection
16636330,166363301,1,I,,20190715,20190726,20190726,EXP,,FR-PRINSTON PHARMACEUTICAL INC.-2019PRN00698,PRINSTON PHARMACEUTICAL,,,,I,,Y,,,20190725,,CN,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Brain herniation;Spina bifida,166363301,DE,,,166363301,1,20050704,20050908,,,,,
16636844,166368441,1,I,,20190718,20190726,20190726,EXP,,PT-MYLANLABS-2019M1069166,MYLAN,,43,YR,,M,Y,,,20190726,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,166368441,OT,,,,,,,,,166368441,1,Hepatitis C
16638680,166386802,2,F,,20190903,20190726,20190909,EXP,,UG-MYLANLABS-2019M1069122,MYLAN,,,,,F,Y,,,20190909,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,166386802,CA,,,166386802,1,20140818,,,,166386802,1,HIV infection
16641527,166415271,1,I,,20190722,20190729,20190729,EXP,,US-HETERO-HET2019US01004,HETERO,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K,METZGER D, MICAN JM, PAU A, LISCO A, LAIDLAW E, HAMMOUD DA, WHITBY D, YARCHOAN R, SERETI I. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS. 2018;5 NO",30,YR,,F,Y,,,20190729,,MD,US,US,Efavirenz+Emtricitabine+Tenofovir,Anaemia;Clostridium difficile colitis;Immune reconstitution inflammatory syndrome associated tuberculosis;Thrombocytopenia,166415271,OT,,,,,,,,,166415271,1,HIV infection
16645051,166450511,1,I,,20190725,20190729,20190729,EXP,,GB-MYLANLABS-2019M1071055,MYLAN,"ORKIN C, SQUIRES KE, MOLINA JM, SAX PE, WONG WW, SUSSMANN O ETAL. DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE IS NON-INFERIOR TO EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE ADULTS WITH  HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTION: WEEK 48 RESULTS OF THE DRIVE-AHEAD TRIAL.. CLINICAL INFECTIOUS DISEASES. 2019;68:535-544",,,A,,Y,,,20190729,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychotic disorder;Suicide attempt,166450511,OT,,,,,,,,,166450511,1,HIV infection
16647278,166472781,1,I,,20190719,20190730,20190730,PER,,US-PFIZER INC-2019323656,PFIZER,,73,YR,,F,Y,131.5,KG,20190730,,CN,US,US,SUSTIVA,Hypothyroidism;Inappropriate schedule of product administration;Weight increased,,,,,,,,,,,166472781,1,Cerebrovascular accident prophylaxis
16648472,166484722,2,F,,20190801,20190730,20190808,EXP,,US-TEVA-2019-US-1084141,TEVA,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K, ET AL. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS 2018;5:NO. 10.",30,YR,,F,Y,,,20190808,,MD,US,US,Efavirenz/tenofovir/emtricitabine,Anaemia;Castleman's disease;Immune reconstitution inflammatory syndrome associated tuberculosis;Lymph node abscess;Paradoxical drug reaction,166484722,HO,,,,,,,,,166484722,1,Immune reconstitution inflammatory syndrome associated tuberculosis
16649549,166495491,1,I,2012,20190723,20190730,20190730,EXP,,"AT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-002333",BOEHRINGER INGELHEIM,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,,,,M,Y,,,20190730,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166495491,OT,,,166495491,1,20120419,20121203,,,166495491,1,Antiretroviral therapy
16652764,166527641,1,I,,20190716,20190731,20190731,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-04388,HIKMA,"MANION M, ULDRICK T, POLIZZOTTO M, SHEIKH V, ROBY G, LURAIN K, METZGER D, MICAN J, PAU A, LISCO A, LAIDLAW E, HAMMOUD D, WHITBY D, YARCHOAN R, SERETI I. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN FORUM INFECTED DISEASE; DI: 10.1093/OFID/OFY217. 2018;5(10):.",30,YR,,F,Y,,,20190731,,MD,US,US,EFAVIRENZ.,Castleman's disease;Kaposi's sarcoma,166527641,OT,,,,,,,,,166527641,1,Immune reconstitution inflammatory syndrome associated tuberculosis
16653573,166535731,1,I,20190727,20190727,20190731,20190731,EXP,,GB-GILEAD-2019-0420659,GILEAD,,,,A,M,Y,,,20190731,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial fibrillation,166535731,OT,,,,,,,,,166535731,1,Product used for unknown indication
16653813,166538131,1,I,,20190725,20190731,20190731,EXP,,GB-MYLANLABS-2019M1071574,MYLAN,,53,YR,,M,Y,,,20190731,,CN,GB,GB,EFAVIRENZ.;EFAVIRENZ/EMTRICITABINE/TENOFOVIRDISOPROXIL T,Arthropathy,166538131,OT,,,,,,,,,166538131,1,Product used for unknown indication
16656457,166564571,1,I,,20190729,20190801,20190801,EXP,,FR-GILEAD-2019-0420924,GILEAD,,,,,,Y,,,20190801,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Osteopenia;Osteoporosis,166564571,OT,,,,,,,,,166564571,1,Product used for unknown indication
16662141,166621415,5,F,2012,20190927,20190802,20190930,EXP,,PHHY2019AT170861,SANDOZ,SCHALK WH. DUAL ART IN THE MANAGEMENT OF ADVERSE EVENTS. JATROS INFEKTIOLOGIE + GASTROENTEROLOGIE. 2019;22,69,YR,,M,Y,90,KG,20190930,,OT,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166621415,OT,,,166621415,1,20031107,20040423,,,166621415,1,Antiretroviral therapy
16663673,166636732,2,F,2012,20190726,20190802,20190805,EXP,,AT-JNJFOC-20190735116,JOHNSON AND JOHNSON,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;.,69,YR,,M,Y,,,20190805,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166636732,OT,,,166636732,1,20111107,20120419,,,166636732,1,Antiviral treatment
16663985,166639851,1,I,,20190404,20190802,20190802,EXP,,IT-MYLANLABS-2019M1032806,MYLAN,"CATTANEO D, GIACOMELLI A, GERVASONI C.. LOSS OF CONTROL OF HIV VIREMIA WITH OTC WEIGHT-LOSS DRUGS: A CALL FOR CAUTION. OBESITY. 2018;26(8):1251-2",39,YR,,F,Y,,,20190802,,MD,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,166639851,OT,,,,,,,,,166639851,1,HIV infection
16666818,166668181,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421672,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,166668181,CA,,,,,,,,,166668181,1,HIV infection
16667411,166674111,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421667,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Holoprosencephaly,166674111,CA,,,,,,,,,166674111,1,HIV infection
16667558,166675581,1,I,20181022,20190725,20190805,20190805,EXP,,GB-MYLANLABS-2019M1072307,MYLAN,,35,YR,,F,Y,,,20190805,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,166675581,OT,,,,,,,,,166675581,1,HIV infection
16667632,166676321,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421543,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrocephalus,166676321,CA,,,,,,,,,166676321,1,HIV infection
16667679,166676791,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421975,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrocephalus,166676791,CA,,,,,,,,,166676791,1,HIV infection
16667707,166677071,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421968,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677071,CA,,,,,,,,,166677071,1,HIV infection
16667754,166677541,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421692,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677541,CA,,,,,,,,,166677541,1,HIV infection
16667778,166677781,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421978,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrocephalus,166677781,CA,,,,,,,,,166677781,1,HIV infection
16667779,166677791,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421969,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677791,CA,,,,,,,,,166677791,1,HIV infection
16667780,166677801,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421976,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrocephalus,166677801,OT,,,,,,,,,166677801,1,HIV infection
16667782,166677821,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421977,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrocephalus,166677821,OT,,,,,,,,,166677821,1,HIV infection
16667916,166679161,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421705,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,166679161,CA,,,,,,,,,166679161,1,HIV infection
16667918,166679181,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421972,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,166679181,OT,,,,,,,,,166679181,1,HIV infection
16667954,166679541,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421994,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679541,CA,,,,,,,,,166679541,1,HIV infection
16667961,166679611,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421673,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679611,OT,,,,,,,,,166679611,1,HIV infection
16667962,166679621,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421993,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679621,OT,,,,,,,,,166679621,1,HIV infection
16668007,166680071,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421995,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166680071,OT,,,,,,,,,166680071,1,HIV infection
16668028,166680281,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421973,GILEAD,,,,,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningocele;Meningomyelocele,166680281,CA,,,,,,,,,166680281,1,HIV infection
16668040,166680401,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421528,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningocele;Meningomyelocele,166680401,OT,,,,,,,,,166680401,1,HIV infection
16668105,166681051,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421683,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681051,OT,,,,,,,,,166681051,1,HIV infection
16668159,166681591,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421997,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681591,CA,,,,,,,,,166681591,1,HIV infection
16668160,166681601,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421998,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681601,CA,,,,,,,,,166681601,1,HIV infection
16668169,166681691,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421982,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166681691,CA,,,,,,,,,166681691,1,HIV infection
16668170,166681701,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421984,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166681701,OT,,,,,,,,,166681701,1,HIV infection
16668202,166682021,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421983,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682021,OT,,,,,,,,,166682021,1,HIV infection
16668203,166682031,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421670,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682031,CA,,,,,,,,,166682031,1,HIV infection
16668212,166682121,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421985,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682121,OT,,,,,,,,,166682121,1,HIV infection
16668263,166682631,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421693,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb malformation,166682631,CA,,,,,,,,,166682631,1,HIV infection
16668269,166682691,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421684,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital foot malformation;Congenital hand malformation;Foetal exposure during pregnancy,166682691,CA,,,,,,,,,166682691,1,HIV infection
16668282,166682821,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421986,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682821,CA,,,,,,,,,166682821,1,HIV infection
16668318,166683181,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421695,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb reduction defect,166683181,OT,,,,,,,,,166683181,1,HIV infection
16668342,166683421,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421987,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683421,OT,,,,,,,,,166683421,1,HIV infection
16668343,166683431,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421988,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683431,CA,,,,,,,,,166683431,1,HIV infection
16668356,166683561,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421989,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683561,CA,,,,,,,,,166683561,1,HIV infection
16668357,166683571,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421696,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb reduction defect,166683571,CA,,,,,,,,,166683571,1,HIV infection
16668381,166683811,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421990,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683811,CA,,,,,,,,,166683811,1,HIV infection
16668397,166683971,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421991,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683971,CA,,,,,,,,,166683971,1,HIV infection
16668399,166683991,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421682,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amniotic band syndrome;Exposure during pregnancy,166683991,OT,,,,,,,,,166683991,1,HIV infection
16668516,166685161,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421694,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital inguinal hernia;Foetal exposure during pregnancy,166685161,OT,,,,,,,,,166685161,1,HIV infection
16668521,166685211,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422003,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166685211,CA,,,,,,,,,166685211,1,HIV infection
16668526,166685261,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421535,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Foetal exposure during pregnancy,166685261,CA,,,,,,,,,166685261,1,HIV infection
16668568,166685681,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421669,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip;Foetal exposure during pregnancy,166685681,OT,,,,,,,,,166685681,1,HIV infection
16668697,166686971,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422004,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166686971,OT,,,,,,,,,166686971,1,HIV infection
16668717,166687171,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422002,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687171,OT,,,,,,,,,166687171,1,HIV infection
16668723,166687231,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421980,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip;Foetal exposure during pregnancy,166687231,OT,,,,,,,,,166687231,1,HIV infection
16668770,166687701,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422005,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687701,OT,,,,,,,,,166687701,1,HIV infection
16668771,166687711,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421671,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,166687711,CA,,,,,,,,,166687711,1,HIV infection
16668772,166687721,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422012,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,166687721,OT,,,,,,,,,166687721,1,HIV infection
16668784,166687841,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422007,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687841,CA,,,,,,,,,166687841,1,HIV infection
16668800,166688001,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422006,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166688001,CA,,,,,,,,,166688001,1,HIV infection
16668812,166688121,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421685,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688121,OT,,,,,,,,,166688121,1,HIV infection
16668829,166688291,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422000,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688291,OT,,,,,,,,,166688291,1,HIV infection
16668867,166688671,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421686,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688671,OT,,,,,,,,,166688671,1,HIV infection
16668872,166688721,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422001,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688721,OT,,,,,,,,,166688721,1,HIV infection
16668873,166688731,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422010,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688731,OT,,,,,,,,,166688731,1,HIV infection
16668876,166688761,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0422008,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166688761,OT,,,,,,,,,166688761,1,HIV infection
16668889,166688891,1,I,,20190726,20190805,20190805,EXP,,BW-GILEAD-2019-0421967,GILEAD,,,,N,,Y,,,20190805,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Holoprosencephaly,166688891,CA,,,,,,,,,166688891,1,HIV infection
16669370,166693701,1,I,20150806,20190801,20190805,20190805,EXP,,ZA-GILEAD-2019-0421790,GILEAD,"ROSSOUW TM, VAN DYK G, VAN ZYL G. RAPID EMERGENCE OF RESISTANCE TO ANTIRETROVIRAL TREATMENT AFTER UNDISCLOSED PRIOR EXPOSURE: A CASE REPORT. S AFR J HIV MED. 2019;20(1):A965. DOI:10.4102/SAJHIVMED.V20I1.965",43,YR,A,F,Y,,,20190805,,OT,ZA,ZA,EFAVIRENZ.,Drug ineffective;Genotype drug resistance test positive,166693701,OT,,,166693701,1,20140806,,,,166693701,1,HIV infection
16671350,166713501,1,I,2012,20190722,20190806,20190806,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-073480,BRISTOL MYERS SQUIBB,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;2:22,,,,M,Y,,,20190806,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166713501,OT,,,166713501,1,20040423,20140606,,,166713501,1,Antiretroviral therapy
16674551,166745512,2,F,,20190912,20190806,20190916,EXP,,AT-VIIV HEALTHCARE LIMITED-AT2019139261,VIIV,"TOUZEAU V,. RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2011;22(6):350-60",39,YR,,F,Y,,,20190916,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745512,HO,,,,,,,,,166745512,1,Antiretroviral therapy
16674552,166745522,2,F,,20190912,20190806,20190917,EXP,,AT-GLAXOSMITHKLINE-AT2019139261,GLAXOSMITHKLINE,"TOUZEAU V,. RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2011;22(6):350-60",39,YR,,F,Y,,,20190917,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745522,OT,,,,,,,,,166745522,1,Antiretroviral therapy
16677491,166774911,1,I,,20190724,20190807,20190807,EXP,,IT-AUROBINDO-AUR-APL-2019-046191,AUROBINDO,,,,,,Y,,,20190807,,OT,IT,IT,Efavirenz Film Coated Tablets,Blood HIV RNA increased,166774911,OT,,,,,,,,,166774911,1,HIV infection
16678561,166785611,1,I,,20190730,20190807,20190807,EXP,,GB-MYLANLABS-2019M1072699,MYLAN,,40,YR,,F,Y,,,20190807,,OT,UG,UG,EFAVIRENZ.,Anticoagulation drug level above therapeutic;Drug interaction;Epistaxis,166785611,OT,,,,,,,,,166785611,1,Tuberculosis
16684765,166847651,1,I,,20190802,20190808,20190808,EXP,,GB-MYLANLABS-2019M1073847,MYLAN,,,,,M,Y,,,20190808,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Perineal abscess,166847651,HO,,,,,,,,,166847651,1,Product used for unknown indication
16689354,166893542,2,F,2019,20190802,20190809,20190814,EXP,,BY-JNJFOC-20190740287,JOHNSON AND JOHNSON,,40,YR,,M,Y,60,KG,20190814,,MD,BY,BY,EFAVIRENZ.,Disseminated tuberculosis,166893542,DE,,,166893542,1,20190605,20190616,,,166893542,1,Tuberculosis
16692421,166924211,1,I,20190616,20190807,20190812,20190812,EXP,,PHHY2019BY185419,NOVARTIS,,40,YR,,M,Y,,,20190812,,CN,BY,BY,EFAVIRENZ.,Multiple organ dysfunction syndrome,166924211,DE,,,166924211,1,20190605,20190615,,,166924211,1,Tuberculosis
16700440,167004401,1,I,,20190805,20190814,20190814,EXP,,ZA-CIPLA LTD.-2019ZA05705,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM.. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA - A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190814,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention,167004401,OT,,,,,,,,,167004401,1,HIV infection
16702036,167020361,1,I,,20190813,20190814,20190814,EXP,,US-GILEAD-2019-0423268,GILEAD,,59,YR,A,M,Y,,,20190814,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder;Fatigue;Nightmare;Vision blurred,167020361,OT,,,167020361,1,200401,,,,167020361,1,HIV infection
16702813,167028131,1,I,,20190808,20190814,20190814,EXP,,TH-MYLANLABS-2019M1076139,MYLAN,,27,YR,,M,Y,,,20190814,,OT,TH,TH,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Penicillium infection;Unmasking of previously unidentified disease,167028131,HO,,,,,,,,,167028131,1,Acquired immunodeficiency syndrome
16704866,167048661,1,I,,20190812,20190814,20190814,EXP,,US-GILEAD-2019-0423564,GILEAD,N. MAOUELAININ; J. ILUSTRE; R. PROMISLOFF. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PCP PNEUMONIA + ACUTE RESPIRATORY FAILURE. AM J RESPIR CRIT CARE MED. 2019;UNK:UNK,41,YR,A,M,Y,,,20190814,,MD,US,US,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,167048661,OT,,,,,,,,,167048661,1,HIV infection
16705848,167058481,1,I,2009,20190802,20190815,20190815,EXP,,MX-GILEAD-2019-0423594,GILEAD,,56,YR,A,F,Y,,,20190815,,OT,MX,MX,EFAVIRENZ.,Chronic kidney disease;Fanconi syndrome acquired;Renal failure,167058481,OT,,,167058481,1,2009,2013,,,167058481,1,HIV infection
16705908,167059082,2,F,2003,20190807,20190815,20190918,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019GSK146156,VIIV,,12,YR,,F,Y,,,20190918,,OT,BR,BR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Papilloma viral infection,167059082,OT,,,,,,,,,167059082,1,HIV infection CDC category A
16705911,167059112,2,F,2003,20190807,20190815,20190918,EXP,,BR-GLAXOSMITHKLINE-BR2019GSK146156,GLAXOSMITHKLINE,,12,YR,,F,Y,,,20190918,,OT,BR,BR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Papilloma viral infection,167059112,OT,,,,,,,,,167059112,1,HIV infection CDC category A
16707501,167075011,1,I,,20190802,20190815,20190815,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-077618,BRISTOL MYERS SQUIBB,,64,YR,,M,Y,,,20190815,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167075011,OT,,,167075011,1,201906,,,,167075011,1,HIV infection
16708256,167082561,1,I,,20190802,20190816,20190816,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-077453,BRISTOL MYERS SQUIBB,,59,YR,,M,Y,,,20190816,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167082561,OT,,,167082561,1,201809,,,,167082561,1,HIV infection
16708486,167084861,1,I,2008,20190805,20190816,20190816,EXP,,ZA-CIPLA LTD.-2019ZA05699,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA- A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190816,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;Generalised tonic-clonic seizure;Insomnia,167084861,OT,,,,,,,,,167084861,1,HIV infection
16708732,167087321,1,I,,20190805,20190816,20190816,EXP,,ZA-CIPLA LTD.-2019ZA05700,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA- A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10 (742):1 TO 10",,,,,Y,,,20190816,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention;Fine motor delay;Generalised tonic-clonic seizure;Speech disorder,167087321,OT,,,,,,,,,167087321,1,HIV infection
16708759,167087592,2,F,,20190917,20190816,20190926,EXP,,ZA-CIPLA LTD.-2019ZA05698,CIPLA,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA- A RETROSPECTIVE CASE SERIES. FRONTIERS IN NEUROLOGY. 2019;10:742:1 TO 10",,,,,Y,,,20190926,,OT,ZA,ZA,EFAVIRENZ.,Ataxia;Developmental regression;Drug level increased;Dysarthria;Generalised tonic-clonic seizure;Incorrect dose administered;Neurotoxicity;Somnolence,167087592,HO,,,,,,,,,167087592,1,Pulmonary tuberculosis
16709578,167095781,1,I,201707,20190808,20190816,20190816,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK146309,VIIV,"ZHU K, ZHU Z, ZHU X, WANG Y.. ANALYSIS OF RELATED FACTORS OF SEVERE MYELOSUPPRESSION IN 3 PATIENTS WITH AIDS RELATED LYMPHOMA AFTER CHEMOTHERAPY. CLINICAL MEDICINE PRACTICE. 2019;28 (2):91-96, DOI:10.16047/J.CNKI.CN1",34,YR,,M,Y,,,20190816,,OT,CN,CN,EFAVIRENZ.,Anaemia;Bone marrow failure;Drug interaction;Granulocytosis;Haemoglobin decreased;Neutropenia;Pulmonary mycosis;Pyrexia,167095781,OT,,,167095781,2,20170615,,,,167095781,1,Acquired immunodeficiency syndrome
16711062,167110621,1,I,,20190808,20190816,20190816,EXP,,CA-TEVA-2019-CA-1091619,TEVA,,52,YR,,M,Y,,,20190816,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167110621,OT,,,,,,,,,167110621,1,HIV infection
16713049,167130491,1,I,,20190803,20190817,20190817,EXP,,GB-AUROBINDO-AUR-APL-2019-054693,AUROBINDO,,,,,,Y,,,20190817,,MD,GB,GB,EFAVIRENZ.,Renal impairment,167130491,OT,,,167130491,1,201906,,,,167130491,1,HIV infection
16715201,167152012,2,F,,20190812,20190819,20190822,EXP,,JP-ACCORD-151382,ACCORD,"HAYAKAWA Y, KOBAYASHI K, SAKAMOTO N, MATSUOKA M, NOZAKA T, MISUMI Y, ET AL,  A CASE OF ESOPHAGEAL CANCER WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION THAT PROGRESSED RAPIDLY AFTER  NEOADJUVANT CHEMORADIOTHERAPY. CLIN J GASTROENTEROL. 2019 JUL 27.",8,DEC,,F,Y,,,20190822,,OT,JP,JP,EFAVIRENZ.,Drug interaction;Nausea;Radiation oesophagitis;Renal impairment,167152012,OT,,,,,,,,,167152012,1,Oesophageal squamous cell carcinoma stage III
16721263,167212631,1,I,201903,20190710,20190820,20190820,EXP,,US-ABBVIE-19K-163-2849740-00,ABBVIE,,65,YR,,M,Y,95.34,KG,20190820,,CN,US,US,SUSTIVA,Aphasia;Cerebrovascular accident;Disorientation;Infection;Pyrexia,167212631,HO,,,167212631,1,20170201,201904,,,167212631,1,Psoriatic arthropathy
16722988,167229882,2,F,201807,20190828,20190821,20190909,EXP,,CA-APOTEX-2019AP020584,APOTEX,"TSENG AL, WONG AYJ, MCLELLAND CJ, WALMSLEY SL. DRUG INTERACTIONS ARE NOT ALWAYS PREDICTABLE: THE CURIOUS CASE OF VALPROIC ACID AND DOLUTEGRAVIR AND A POSSIBLE EXPLANATION. DOI:10.1097/QAD.0000000000002256. AIDS. 2019;33(10):1677-1679",43,YR,,F,Y,,,20190909,,OT,CA,CA,EFAVIRENZ.,Drug interaction;Drug level below therapeutic;Seizure,167229882,OT,,,167229882,4,2016,,,,167229882,1,Cerebrovascular accident
16724673,167246731,1,I,,20190813,20190821,20190821,EXP,,CA-MYLANLABS-2019M1077398,MYLAN,"TSENG AL, WONG AYJ, MCLELLAND CJ, WALMSLEY SL. DRUG INTERACTIONS ARE NOT ALWAYS PREDICTABLE: THE CURIOUS CASE OF VALPROIC ACID AND DOLUTEGRAVIR AND A POSSIBLE EXPLANATION. AIDS 2019;33(10):1677-1679.",43,YR,,F,Y,,,20190821,,PH,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction,167246731,OT,,,167246731,1,2016,2018,,,167246731,1,HIV infection
16728623,167286231,1,I,,20190808,20190822,20190822,EXP,,CA-AUROBINDO-AUR-APL-2019-054269,AUROBINDO,,,,,,Y,,,20190822,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,167286231,OT,,,,,,,,,167286231,1,Product used for unknown indication
16728651,167286511,1,I,,20190808,20190822,20190822,EXP,,CA-AUROBINDO-AUR-APL-2019-054602,AUROBINDO,,,,,,Y,,,20190822,,OT,CA,CA,Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,167286511,CA,,,,,,,,,167286511,1,HIV infection
16728652,167286521,1,I,,20190808,20190822,20190822,EXP,,CA-AUROBINDO-AUR-APL-2019-054273,AUROBINDO,,,,,,Y,,,20190822,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167286521,OT,,,,,,,,,167286521,1,HIV infection
16730728,167307281,1,I,,20190819,20190822,20190822,EXP,,JP-PFIZER INC-2019358649,PFIZER,"YANAGISAWA, N.. LARGE ABSCESS FORMED IN THE ABDOMINAL WALL BY MYCOBACTERIUM AVIUM COMPLEX: A CASE OF UNMASKING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. IDCASES. 2019;18:10.1016/J.IDCR.2019.E00609",51,YR,,M,Y,,,20190822,,PH,JP,JP,EFAVIRENZ.,Renal impairment,167307281,OT,,,,,,,,,167307281,1,Mycobacterium avium complex infection
16731952,167319521,1,I,20170517,20170704,20190822,20190822,EXP,,US-EXELIXIS-XL18417009703,EXELIXIS,,64,YR,,M,Y,112.4,KG,20190822,,MD,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Cardiac arrest;Staphylococcal infection,167319521,LT,,,167319521,1,20140121,20170517,,,167319521,1,Neoplasm
16734269,167342692,2,F,,20190911,20190823,20190924,EXP,,CA-AUROBINDO-AUR-APL-2019-054545,AUROBINDO,,54,YR,,M,Y,,,20190925,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,167342692,OT,,,,,,,,,167342692,1,Bipolar disorder
16734522,167345221,1,I,,20190809,20190823,20190823,EXP,,CA-AUROBINDO-AUR-APL-2019-055314,AUROBINDO,,,,,,Y,,,20190823,,PH,CA,CA,EFAVIRENZ.,Hip fracture;Osteopenia;Osteoporosis;Spinal compression fracture,167345221,OT,,,,,,,,,167345221,1,HIV infection
16734610,167346101,1,I,,20190809,20190823,20190823,EXP,,CA-AUROBINDO-AUR-APL-2019-054681,AUROBINDO,,,,,,Y,,,20190823,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,167346101,OT,,,,,,,,,167346101,1,Product used for unknown indication
16736725,167367251,1,I,,20190812,20190823,20190823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-082814,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190823,,OT,ZA,ZA,EFAVIRENZ.,Neurotoxicity,167367251,OT,,,,,,,,,167367251,1,HIV infection
16736844,167368441,1,I,,20190812,20190823,20190823,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-081257,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190823,,OT,ZA,ZA,EFAVIRENZ.,Accidental overdose;Neurotoxicity,167368441,OT,,,,,,,,,167368441,1,HIV infection
16737882,167378822,2,F,,20190813,20190824,20190917,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004747,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190917,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167378822,OT,,,,,,,,,167378822,1,HIV infection
16740232,167402321,1,I,,20190813,20190826,20190826,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080274,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190826,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,167402321,OT,,,,,,,,,167402321,1,Product used for unknown indication
16741197,167411971,1,I,,20190813,20190826,20190826,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080347,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190826,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,167411971,OT,,,,,,,,,167411971,1,Product used for unknown indication
16741532,167415321,1,I,,20190813,20190826,20190826,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190826,,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,167415321,OT,,,,,,,,,167415321,1,HIV infection
16745875,167458752,2,F,,20190827,20190827,20190903,EXP,PT-EMA-DD-20181218-KUMARVN_P-173122,PT-MYLANLABS-2019M1079394,MYLAN,"RAPOSO AF, ANTUNES AP, STRECHT T, ALVES SC, OLIVEIRA C, GUIMARAES M, ET AL... PHARMACOLOGICAL COMPLEXITY IN HIV-INFECTED PATIENTS. 23RD NATIONAL INTERNAL MEDICINE CONGRESS. 2017;23:1",49,YR,,M,Y,,,20190903,,OT,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,167458752,OT,,,,,,,,,167458752,1,Product used for unknown indication
16747443,167474431,1,I,,20190822,20190827,20190827,EXP,,CA-TEVA-2019-CA-1099318,TEVA,,57,YR,,M,Y,,,20190827,,PH,CA,CA,TEVA-EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Agitation;Anxiety;Depression;Diarrhoea;Feeling of despair;Mania;Product substitution issue;Suicidal ideation,167474431,LT,,,,,,,,,167474431,1,HIV infection
16747469,167474691,1,I,,20190822,20190827,20190827,EXP,,CA-TEVA-2019-CA-1099329,TEVA,,56,YR,,M,Y,,,20190827,,PH,CA,CA,TEVA-EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Abdominal discomfort;Product substitution issue,167474691,OT,,,,,,,,,167474691,1,HIV infection
16748110,167481101,1,I,2016,20190826,20190827,20190827,EXP,FR-AFSSAPS-RN20191169,FR-GILEAD-2019-0425401,GILEAD,,68,YR,E,M,Y,82,KG,20190827,,CN,FR,FR,SUSTIVA,Ageusia;Anosmia;Renal failure,167481101,OT,,,167481101,1,20160201,,,,167481101,1,HIV test positive
16749585,167495851,1,I,,20190826,20190828,20190828,EXP,,IN-GILEAD-2019-0425464,GILEAD,"CHHABRA M, DAVER RG. MULTIDRUG REGIMEN FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE MOTHERS IN INDIA FROM PREVENTION TOWARD ELIMINATION. UNK. 2019;11:50-57",,,,F,Y,,,20190828,,MD,IN,IN,EFAVIRENZ.,Nephritis,167495851,OT,,,,,,,,,167495851,1,HIV infection
16749785,167497852,2,F,20180117,20190820,20190828,20190828,EXP,,PHHY2019BY197826,NOVARTIS,,58,YR,,F,Y,93.7,KG,20190828,,CN,BY,BY,EFAVIRENZ.,Electrocardiogram QT prolonged;Hepatic enzyme increased;Incorrect product administration duration,167497852,OT,,,167497852,1,20180904,20190208,,,167497852,1,Product used for unknown indication
16751630,167516301,1,I,,20190822,20190828,20190828,EXP,,CA-TEVA-2019-CA-1099324,TEVA,,,,,M,Y,64,KG,20190828,,PH,CA,CA,TEVA- EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Alanine aminotransferase increased;Aspartate aminotransferase increased;Nervous system disorder;Product substitution issue;Rash;Transaminases increased;Urticaria,167516301,OT,,,,,,,,,167516301,1,HIV infection
16754843,167548431,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081032,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,M,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Accidental overdose;Ataxia;Cognitive disorder;Dysarthria;Generalised tonic-clonic seizure;Incorrect dose administered;Neuropsychiatric symptoms;Somnolence;Toxicity to various agents,167548431,OT,,,,,,,,,167548431,1,HIV infection
16754990,167549901,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081042,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549901,OT,,,,,,,,,167549901,1,HIV infection
16754992,167549921,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081033,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549921,OT,,,,,,,,,167549921,1,HIV infection
16754994,167549941,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081037,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167549941,OT,,,,,,,,,167549941,1,HIV infection
16754995,167549951,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081046,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Condition aggravated;Growth retardation;HIV-associated neurocognitive disorder,167549951,OT,,,,,,,,,167549951,1,HIV infection
16754998,167549981,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081040,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Condition aggravated;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder,167549981,OT,,,,,,,,,167549981,1,HIV infection
16755095,167550951,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081048,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder;Microcephaly,167550951,OT,,,,,,,,,167550951,1,HIV infection
16755096,167550961,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081050,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder,167550961,OT,,,,,,,,,167550961,1,HIV infection
16755097,167550971,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081047,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;HIV-associated neurocognitive disorder,167550971,OT,,,,,,,,,167550971,1,HIV infection
16755098,167550981,1,I,,20190822,20190829,20190829,EXP,,ZA-MYLANLABS-2019M1081052,MYLAN,"HAMMOND CK, ELEY B, ING N, WILMSHURST JM. NEUROPSYCHIATRIC AND NEUROCOGNITIVE MANIFESTATIONS IN HIV-INFECTED CHILDREN TREATED WITH EFAVIRENZ IN SOUTH AFRICA-A RETROSPECTIVE CASE SERIES. FRONT-NEUROL 2019;10:742.",,,C,,Y,,,20190829,,OT,ZA,ZA,EFAVIRENZ.,Condition aggravated;Growth retardation;HIV-associated neurocognitive disorder,167550981,OT,,,,,,,,,167550981,1,HIV infection
16762184,167621841,1,I,,20190819,20190831,20190831,EXP,,TH-HETERO-HET2019TH01170,HETERO,"PONGPECH N, ROTJANAPAN P. ABSENCE OF CUTANEOUS INVOLVEMENT IN DISSEMINATED TALAROMYCES MARNEFFEI INFECTION IN AN AIDS PATIENT: A CASE REPORT AND LITERATURE REVIEW. INFECT-DRUG-RESIST. 2019;12:1493-1499",27,YR,,M,Y,,,20190831,,OT,TH,TH,EFAVIRENZ.,Fungal infection;Immune reconstitution inflammatory syndrome,167621841,OT,,,,,,,,,167621841,1,Acquired immunodeficiency syndrome
16764331,167643311,1,I,,20190823,20190902,20190902,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK157091,VIIV,"STEEGEN K, VAN ZYL G, LETSOALO E, CLAASSEN M, HANS L, CARMONA S.. RESISTANCE IN PATIENTS FAILING INTEGRASE STRAND TRANSFER INHIBITORS: A CALL TO REPLACE RALTEGRAVIR WITH DOLUTEGRAVIR IN THIRD-LINE TREATMENT IN SOUTH AFRICA. OPEN FORUM INFECTIOUS DISEASES. 2019;DOI: HTTPS://DOI.ORG/10.1093/O",57,YR,,,Y,,,20190902,,MD,ZA,ZA,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,167643311,OT,,,,,,,,,167643311,1,HIV infection
16768439,167684391,1,I,201004,20190827,20190903,20190903,EXP,,LT-MYLANLABS-2019M1081910,MYLAN,,42,YR,,M,Y,,,20190903,,MD,LT,LT,EFAVIRENZ.,Drug resistance;Extrapulmonary tuberculosis;Lymph node tuberculosis;Viraemia,167684391,OT,,,167684391,1,20100324,201110,,,167684391,1,Product used for unknown indication
16769151,167691511,1,I,,20190827,20190903,20190903,EXP,,US-MYLANLABS-2019M1082620,MYLAN,"KANG-BIRKEN SL, EL-SAYED D, PRICHARD J. HIV VIRAL REBOUND DUE TO A POSSIBLE DRUG-DRUG INTERACTION BETWEEN ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE AND CALCIUM-CONTAINING PRODUCTS: REPORT OF 2 CASES. J-INT-ASSOC-PROVID-AIDS-CARE 2019;:.",35,YR,,F,Y,,,20190903,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Pathogen resistance;Pyrexia;Rash morbilliform;Transaminases increased,167691511,OT,,,167691511,4,201610,,,,167691511,1,Supplementation therapy
16770969,167709691,1,I,2016,20190823,20190904,20190904,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-083948,BRISTOL MYERS SQUIBB,,68,YR,,M,Y,82,KG,20190904,,CN,FR,FR,SUSTIVA,Ageusia;Anosmia;Renal failure,167709691,OT,,,167709691,1,2016,,,,167709691,1,HIV test positive
16773759,167737591,1,I,,20190828,20190904,20190904,EXP,,PHHY2019IN200997,SANDOZ,,51,YR,,F,Y,,,20190905,,OT,BR,IN,EFAVIRENZ.,Abdominal pain;Central nervous system immune reconstitution inflammatory response;Hepatic congestion;Hepatotoxicity;Jaundice;Lymphadenopathy;Pruritus generalised;Pyrexia;Seizure;Tuberculoma of central nervous system,167737591,OT,,,167737591,2,20100508,20101206,,,167737591,1,HIV infection
16774592,167745921,1,I,,20190830,20190905,20190905,EXP,,IN-STRIDES ARCOLAB LIMITED-2019SP008323,STRIDES,,35,YR,,F,Y,,,20190905,,,NL,IN,EFAVIRENZ.,Dysphagia;Erythema multiforme;Fixed eruption;Lip discolouration;Mouth ulceration;Oral discomfort;Oral mucosal discolouration;Tongue discolouration,167745921,OT,,,,,,,,,167745921,1,Postoperative analgesia
16778673,167786731,1,I,,20190822,20190906,20190906,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086418,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20190906,,MD,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,167786731,OT,,,,,,,,,167786731,1,HIV infection
16778679,167786791,1,I,,20190822,20190906,20190906,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086419,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190906,,MD,US,US,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,167786791,CA,,,,,,,,,167786791,1,Product used for unknown indication
16786119,167861191,1,I,,20190825,20190909,20190909,EXP,,IN-PURACAP PHARMACEUTICAL LLC-2019EPC00238,PURACAP,"SAI PAWAN AR, SWAMY VHT, MOTHI SN, YASHASWINI Y.. IBUPROFEN-INDUCED INTRA-ORAL FIXED DRUG ERUPTION. J PHARM PRACT RES.. 2019",35,YR,,F,Y,,,20190909,,PH,IN,IN,EFAVIRENZ.,Fixed eruption,167861191,OT,,,,,,,,,167861191,1,Postoperative analgesia
16792120,167921201,1,I,,20190902,20190910,20190910,EXP,,US-TEVA-2019-US-1105350,TEVA,"KANG-BIRKEN SL, EL-SAYED D, PRICHARD J. HIV VIRAL REBOUND DUE TO A POSSIBLE DRUG-DRUG INTERACTION BETWEEN ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE AND CALCIUM-CONTAINING PRODUCTS: REPORT OF 2 CASES. J-INT-ASSOC-PROVID-AIDS-CARE 2019;:.",35,YR,,F,Y,,,20190910,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Pathogen resistance;Pyrexia;Rash morbilliform;Transaminases increased,167921201,HO,,,167921201,4,201703,,,,167921201,1,Supplementation therapy
16794386,167943861,1,I,,20190902,20190911,20190911,EXP,,ES-TEVA-2019-ES-1105202,TEVA,"KWON M, BAILEN R, BALSALOBRE P, JURADO M, BERMUDEZ A, BADIOLA J, ET AL. ALLOGENEIC STEM-CELL TRANSPLANTATION IN HIV-1-INFECTED PATIENTS WITH HIGH-RISK HEMATOLOGICAL DISORDERS. AIDS 2019;33(9):1441-1447.",,,A,,Y,,,20190911,,MD,ES,ES,EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Drug interaction;Hepatotoxicity;Neurotoxicity,167943861,OT,,,,,,,,,167943861,1,HIV infection
16795810,167958102,2,F,201510,20190910,20190911,20190917,EXP,,CH-GILEAD-2019-0427660,GILEAD,,53,YR,A,M,Y,,,20190917,,OT,CH,CH,EFAVIRENZ.,Hepatic cirrhosis;Hepatitis B;Hepatitis D;Hepatocellular injury;Liver transplant,167958102,OT,,,,,,,,,167958102,1,HIV infection
16795975,167959751,1,I,1996,20190905,20190911,20190911,EXP,,"ES-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-100655",BOEHRINGER INGELHEIM,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A,. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLIN DRUG INVEST.. 2019;UNK:UNK. DOI:10.1007/S40261-019-00829-X",38,YR,,M,Y,,,20190911,,OT,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,167959751,OT,,,167959751,1,2001,2002,,,167959751,1,Antiretroviral therapy
16799645,167996452,2,F,,20190916,20190912,20190918,EXP,,ZA-GILEAD-2019-0427152,GILEAD,,18,YR,A,F,Y,,,20190918,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Bradycardia foetal;Drug interaction;Foetal distress syndrome;Maternal exposure during pregnancy,167996452,OT,,,,,,,,,167996452,1,HIV infection
16800956,168009562,2,F,1996,20190916,20190912,20190920,EXP,,PHHY2019ES207545,SANDOZ,,38,YR,,M,Y,,,20190920,,OT,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,168009562,OT,,,168009562,14,2013,201510,,,168009562,1,Antiretroviral therapy
16801483,168014831,1,I,,20190903,20190912,20190912,EXP,,FR-MYLANLABS-2019M1084035,MYLAN,,25,YR,,F,Y,,,20190912,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Intentional product misuse;Treatment noncompliance,168014831,OT,,,,,,,,,168014831,1,Product used for unknown indication
16801916,168019161,1,I,,20190906,20190912,20190912,EXP,,DE-MYLANLABS-2019M1084461,MYLAN,"RADMER S, KASTIRR I, ANDERSEN R.. OBSERVATION OF RECURRENT BONE MARROW OEDEMAS IN HIV PATIENTS ON ANTIVIRAL THERAPY. 2016 (ASBMR). ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH. 2016",62,YR,,M,Y,,,20190912,,,COUNTRY NOT SPECIFIED,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema;Foot fracture;Renal failure,168019161,OT,,,,,,,,,168019161,1,HIV infection
16802468,168024681,1,I,,20190905,20190912,20190912,EXP,,ES-ABBVIE-19P-144-2915335-00,ABBVIE,"KWON M, BAILEN R, BALSALOBRE P, ET AL. ALLOGENEIC STEM-CELL TRANSPLANTATION IN HIV-1-INFECTED PATIENTS WITH HIGH-RISK HEMATOLOGICAL DISORDERS. AIDS. 2019;33 (9):1441-1447.",,,A,,Y,,,20190912,,MD,COUNTRY NOT SPECIFIED,ES,EFAVIRENZ.,Blood HIV RNA;Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,168024681,OT,,,168024681,1,2008,,,,168024681,1,HIV infection
16803928,168039281,1,I,20190717,20190904,20190913,20190913,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022900,MACLEODS,,,,,,Y,,,20190913,,CN,US,BR,LAMIVUDINE+ EFAVIRENZ + TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,168039281,OT,,,168039281,1,20170927,,,,168039281,1,HIV infection
16804923,168049231,1,I,20180619,20190909,20190913,20190913,EXP,FR-AFSSAPS-LM20190702,FR-FRESENIUS KABI-FK201909898,FRESENIUS KABI,,57,YR,,M,Y,80,KG,20190913,,OT,NL,FR,EMTRICITABINE/EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE,Anaphylactic shock;Bronchospasm;Circulatory collapse,168049231,LT,,,168049231,1,20180619,20180619,,,168049231,1,General anaesthesia
16806887,168068872,2,F,,20190913,20190913,20190924,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-088376,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20190924,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168068872,OT,,,,,,,,,168068872,1,HIV infection
16806891,168068911,1,I,2001,20190903,20190913,20190913,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20190913,,OT,ES,ES,EFAVIRENZ.,Neurotoxicity,168068911,OT,,,168068911,1,2001,2001,,,168068911,1,HIV infection
16814645,168146451,1,I,,20190903,20190917,20190917,EXP,,ZA-AUROBINDO-AUR-APL-2019-060073,AUROBINDO,,,,C,,Y,,,20190917,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder;Insomnia,168146451,OT,,,,,,,,,168146451,1,HIV infection WHO clinical stage II
16814718,168147181,1,I,,20190912,20190917,20190917,EXP,,CA-TEVA-2019-CA-1109436,TEVA,,,,,M,Y,,,20190917,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,168147181,OT,,,,,,,,,168147181,1,Product used for unknown indication
16815614,168156141,1,I,,20190904,20190917,20190917,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086975,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190917,,OT,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,168156141,OT,,,,,,,,,168156141,1,Product used for unknown indication
16818085,168180851,1,I,,20190905,20190917,20190917,EXP,,GB-JNJFOC-20190910701,JOHNSON AND JOHNSON,"OLIVEIRA R, PATEL RK, TAYLOR C, CZUPRYNSKA J, ARYA R, ROBERTS LN. DIRECT ORAL ANTICOAGULANTS FOR THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH HIV ? A SINGLE CENTRE EXPERIENCE. BRITISH JOURNAL OF HAEMATOLOGY. 2019;186:5:E148-E151",,,A,M,Y,,,20190917,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168180851,OT,,,,,,,,,168180851,1,Embolism venous
16820606,168206061,1,I,,20190912,20190918,20190918,EXP,,CA-TEVA-2019-CA-1109439,TEVA,,54,YR,,M,Y,,,20190918,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,168206061,OT,,,,,,,,,168206061,1,HIV infection
16820699,168206991,1,I,,20190903,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060077,AUROBINDO,,,,C,,Y,,,20190918,,OT,ZA,ZA,EFAVIRENZ.,Disturbance in attention;HIV-associated neurocognitive disorder;Motor dysfunction;Toxicity to various agents,168206991,OT,,,,,,,,,168206991,1,HIV infection
16820781,168207811,1,I,,20190903,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060075,AUROBINDO,,,,C,,Y,,,20190918,,OT,ZA,ZA,EFAVIRENZ.,Ataxia;Developmental regression;Dysarthria;Generalised tonic-clonic seizure;Neurotoxicity;Overdose;Somnolence;Toxicity to various agents,168207811,OT,,,,,,,,,168207811,1,HIV infection WHO clinical stage III
16820800,168208001,1,I,,20190903,20190918,20190918,EXP,,ZA-AUROBINDO-AUR-APL-2019-060076,AUROBINDO,,,,,,Y,,,20190918,,OT,ZA,ZA,EFAVIRENZ.,Attention deficit/hyperactivity disorder;Disturbance in attention;Fine motor delay;Generalised tonic-clonic seizure;HIV-associated neurocognitive disorder;Microcephaly;Speech disorder developmental;Toxicity to various agents,168208001,OT,,,,,,,,,168208001,1,HIV infection
16821359,168213591,1,I,,20190912,20190918,20190918,EXP,,CA-TEVA-2019-CA-1109476,TEVA,,,,,M,Y,,,20190918,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,168213591,OT,,,,,,,,,168213591,1,Product used for unknown indication
16823466,168234661,1,I,,20190910,20190918,20190918,EXP,,PK-GILEAD-2019-0427843,GILEAD,"JAFRY NH, MUBARAK M, ANIS S, AHMED E, AKHTAR F. MYELOMA-LIKE CAST NEPHROPATHY IN A HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT: A CASE REPORT. PORT J NEPHROL HYPERT. 2019;33 (2):118-121. DOI:DOI.ORG/10.32932/PJNH.2019.07.024",27,YR,A,M,Y,,,20190918,,MD,PK,PK,EFAVIRENZ.,Acute kidney injury;Myeloma cast nephropathy,168234661,HO,,,,,,,,,168234661,1,HIV infection
16823614,168236141,1,I,200311,20060103,20190918,20190918,EXP,DJ0500887,FR-VIIV HEALTHCARE LIMITED-B0405145A,VIIV,,36,YR,,F,Y,82,KG,20190918,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,168236141,OT,,,168236141,1,20051010,20051021,,,168236141,1,HIV infection
16824234,168242341,1,I,20070124,20190424,20190918,20190918,EXP,,US-GILEAD-2019-0427889,GILEAD,,26,YR,A,M,Y,,,20190918,,OT,US,US,SUSTIVA,Bilevel positive airway pressure;Blood creatinine increased;Drug-induced liver injury;Fluid imbalance;Hypoalbuminaemia;Hypotension;Intestinal obstruction;Kaposi's sarcoma;Malnutrition;Muscle fatigue;Pleural effusion;Respiratory arrest,168242341,DE,,,,,,,,,168242341,1,Acquired immunodeficiency syndrome
16824327,168243271,1,I,200809,20190910,20190918,20190918,EXP,,ES-MYLANLABS-2019M1086577,MYLAN,,68,YR,,M,Y,69.5,KG,20190918,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis,168243271,OT,,,168243271,1,200805,,,,168243271,1,HIV infection
16826060,168260602,2,F,,20190911,20190919,20190925,EXP,,CA-AUROBINDO-AUR-APL-2019-059880,AUROBINDO,,44,YR,,M,Y,,,20190925,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,168260602,OT,,,,,,,,,168260602,1,Psychotic disorder
16826078,168260781,1,I,,20190904,20190919,20190919,EXP,,CA-AUROBINDO-AUR-APL-2019-059693,AUROBINDO,,44,YR,,M,Y,,,20190919,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,168260781,OT,,,,,,,,,168260781,1,Product used for unknown indication
16829774,168297741,1,I,,20190912,20190919,20190919,EXP,,CA-TEVA-2019-CA-1109359,TEVA,,44,YR,,M,Y,,,20190919,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,168297741,HO,,,,,,,,,168297741,1,HIV infection
16831092,168310921,1,I,20190201,20190917,20190920,20190920,EXP,,US-GILEAD-2019-0428991,GILEAD,,54,YR,A,M,Y,,,20190920,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,168310921,OT,,,,,,,,,168310921,1,HIV infection
16832095,168320951,1,I,,20190905,20190920,20190920,EXP,,ES-AUROBINDO-AUR-APL-2019-060571,AUROBINDO,,,,,,Y,,,20190920,,OT,ES,ES,EFAVIRENZ.,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,168320951,OT,,,168320951,1,2008,,,,168320951,1,HIV infection
16838569,168385691,1,I,,20190918,20190923,20190923,EXP,,CA-ABBVIE-19K-028-2932164-00,ABBVIE,,,,,M,Y,,,20190923,,OT,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,168385691,OT,,,,,,,,,168385691,1,Product used for unknown indication
16845254,168452541,1,I,,20190920,20190924,20190924,EXP,,FR-MYLANLABS-2019M1088737,MYLAN,,,,N,,Y,,,20190924,,CN,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168452541,OT,,,168452541,1,20050704,20050908,,,168452541,1,Product used for unknown indication
16846318,168463181,1,I,,20190923,20190924,20190924,EXP,,FR-MYLANLABS-2019M1089332,MYLAN,,,,N,,Y,,,20190924,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168463181,CA,,,168463181,1,20050523,20050908,,,168463181,1,Product used for unknown indication
16846431,168464311,1,I,,20190917,20190924,20190924,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019AMR168959,VIIV,,,,,M,Y,,,20190924,,OT,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,168464311,OT,,,,,,,,,168464311,1,Product used for unknown indication
16846522,168465221,1,I,,20190920,20190924,20190924,EXP,FR-EMA-DD-20190507-SAHU_K-170342,FR-MYLANLABS-2019M1088784,MYLAN,,,,N,,Y,,,20190924,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168465221,CA,,,168465221,4,20050908,,,,168465221,1,HIV infection
16846790,168467901,1,I,,20190920,20190924,20190924,EXP,,FR-MYLANLABS-2019M1088803,MYLAN,,,,,,Y,,,20190924,,CN,US,FR,EFAVIRENZ.,Encephalocele;Foetal exposure during pregnancy;Spina bifida,168467901,OT,,,,,,,,,168467901,1,Product used for unknown indication
16846793,168467931,1,I,20171006,20190920,20190924,20190924,EXP,,GB-MYLANLABS-2019M1088802,MYLAN,,,,,,Y,,,20190924,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrops foetalis,168467931,CA,,,168467931,1,20171006,,,,168467931,1,HIV infection
16850210,168502101,1,I,,20190916,20190925,20190925,EXP,,ZW-MYLANLABS-2019M1088651,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190925,,MD,ZW,ZW,EFAVIRENZ.,Labelled drug-drug interaction medication error;Neutropenia,168502101,OT,,,,,,,,,168502101,1,HIV infection
16850211,168502111,1,I,,20190916,20190925,20190925,EXP,,ZW-MYLANLABS-2019M1088650,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190925,,MD,ZW,ZW,EFAVIRENZ.,Labelled drug-drug interaction medication error;Neutropenia,168502111,OT,,,,,,,,,168502111,1,HIV infection
16852039,168520391,1,I,,20190920,20190925,20190925,EXP,,US-GILEAD-2019-0429840,GILEAD,,,,,M,Y,,,20190925,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety;Depression;Diabetes mellitus;Pain,168520391,OT,,,,,,,,,168520391,1,HIV infection
16852656,168526561,1,I,,20190920,20190925,20190925,EXP,,FR-MYLANLABS-2019M1088733,MYLAN,,25,YR,,F,Y,,,20190925,,OT,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Insomnia;Vertigo,168526561,OT,,,168526561,1,20050704,20050908,,,168526561,1,HIV infection
16854144,168541441,1,I,,20190912,20190926,20190926,EXP,,GB-AUROBINDO-AUR-APL-2019-062196,AUROBINDO,,,,A,M,Y,,,20190926,,OT,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168541441,OT,,,,,,,,,168541441,1,Product used for unknown indication
16855977,168559771,1,I,,20190916,20190926,20190926,EXP,,ZW-MYLANLABS-2019M1088638,MYLAN,"BWAKURA DANGAREMBIZI M, SAMSON P, CAPPARELLI EV, MOORE CB, JEAN-PHILIPPE P, SPECTOR SA, ET AL. ESTABLISHING DOSING RECOMMENDATIONS FOR EFAVIRENZ IN HIV/TB-COINFECTED CHILDREN YOUNGER THAN 3 YEARS. J-ACQUIR-IMMUNE-DEFIC-SYNDR 2019;81(4):473-480.",,,C,,Y,,,20190926,,MD,ZW,ZW,EFAVIRENZ.,Drug interaction;Drug level increased;Transaminases increased,168559771,OT,,,,,,,,,168559771,1,HIV infection
16856140,168561401,1,I,,20190920,20190926,20190926,PER,,US-PFIZER INC-2019411166,PFIZER,,49,YR,,M,Y,94.8,KG,20190926,,CN,US,US,SUSTIVA,Drug interaction;White blood cell count decreased,,,,,,,,,,,168561401,2,HIV infection
16856401,168564011,1,I,,20190924,20190926,20190926,EXP,,FR-MYLANLABS-2019M1089666,MYLAN,,,,,,Y,,,20190926,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,168564011,CA,,,168564011,1,20050704,20050908,,,168564011,1,Product used for unknown indication
16859830,168598301,1,I,,20190920,20190927,20190927,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092601,BRISTOL MYERS SQUIBB,,,,,M,Y,3.23,KG,20190927,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168598301,OT,,,168598301,1,20070403,20070510,,,168598301,1,Product used for unknown indication
16860477,168604771,1,I,200809,20190924,20190927,20190927,EXP,,ES-MYLANLABS-2019M1089643,MYLAN,,68,YR,,M,Y,69.5,KG,20190927,,MD,ES,ES,EFAVIRENZ.;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis,168604771,OT,,,168604771,1,200805,200905,,,168604771,1,HIV infection
16861796,168617961,1,I,,20190924,20190927,20190927,EXP,,US-GILEAD-2019-0430270,GILEAD,,,,,M,Y,,,20190927,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone loss;Multiple fractures;Renal failure,168617961,DS,,,,,,,,,168617961,1,Product used for unknown indication
16861997,168619971,1,I,,20190923,20190927,20190927,EXP,GB-EMA-DD-20190508-SAHU_K-153427,GB-MYLANLABS-2019M1089322,MYLAN,,43,YR,,F,Y,,,20190927,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168619971,OT,,,,,,,,,168619971,1,HIV infection
16862483,168624831,1,I,,20190923,20190927,20190927,EXP,,FR-MYLANLABS-2019M1089460,MYLAN,,,,,,Y,,,20190927,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,168624831,CA,,,168624831,1,20050513,20050908,,,168624831,1,HIV infection
16862780,168627801,1,I,,20190925,20190927,20190927,EXP,,US-GILEAD-2019-0430355,GILEAD,,35,YR,A,M,Y,,,20190927,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gun shot wound,168627801,OT,,,,,,,,,168627801,1,HIV infection
16863601,168636011,1,I,20190806,20190923,20190927,20190927,EXP,GB-MHRA-EYC 00208628,GB-MYLANLABS-2019M1090380,MYLAN,,69,YR,,M,Y,,,20190927,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal pain upper;Diarrhoea,168636011,DS,,,168636011,2,20190806,20190821,,,168636011,1,Product used for unknown indication
16867501,168675011,1,I,20190301,20190923,20190930,20190930,EXP,GB-MHRA-EYC 00208612,GB-MYLANLABS-2019M1090169,MYLAN,,47,YR,,M,Y,,,20190930,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal distension;Depression;Diarrhoea;Suicidal ideation,168675011,DS,,,168675011,1,20190301,20190501,,,168675011,1,HIV infection
16867869,168678691,1,I,,20190916,20190930,20190930,EXP,,IT-ROCHE-2419096,ROCHE,"BINI T, TESTA L, CHIESA E, ADORNI F, ABELI C, CASTELNUOVO B, MELZI S, SOLLIMA S, BONGIOVANNI M AND D^ARMINIO MONFORTE A OUTCOME OF A SECOND-LINE PROTEASE INHIBITOR-CONTAINING REGIMEN IN PATIENTS FAILING OR INTOLERANT OF A FIRST HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2000 JUN 01;24 (2):115-22.",,,,,Y,,,20190930,,OT,IT,IT,EFAVIRENZ.,Hepatotoxicity,168678691,OT,,,,,,,,,168678691,1,HIV infection
16867931,168679311,1,I,1996,20190916,20190930,20190930,EXP,,ES-ROCHE-2412643,ROCHE,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLIN DRUG INVEST 2019;:-.",38,YR,,M,Y,,,20190930,,OT,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Pathological fracture;Proteinuria;Renal glycosuria;Renal impairment;Virologic failure,168679311,OT,,,168679311,1,1996,1997,,,168679311,1,Antiretroviral therapy
16869360,168693601,1,I,,20190924,20190930,20190930,EXP,,GB-MYLANLABS-2019M1090004,MYLAN,,43,YR,,F,Y,,,20190930,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168693601,OT,,,168693601,2,20171006,,,,168693601,1,HIV infection
16870109,168701091,1,I,,20190926,20190930,20190930,EXP,,GB-MYLANLABS-2019M1091043,MYLAN,,43,YR,,F,Y,,,20190930,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,168701091,OT,,,168701091,1,20171006,,,,168701091,1,HIV infection
3990923,399092310,10,F,20030725,20190902,20030828,20190913,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12363941,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,74,KG,20190913,,OT,FR,FR,SUSTIVA,Aggression;Ascites;Hepatic necrosis;Hepatitis A;Jaundice;Peritoneal haematoma;Somnolence;Vomiting,399092310,LT,,,399092310,1,20030412,20030728,,,399092310,1,HIV infection
5959328,59593282,2,F,200311,20190911,20060112,20190918,EXP,DJ0500887,FR-GLAXOSMITHKLINE-B0405145A,GLAXOSMITHKLINE,,36,YR,,F,Y,82,KG,20190918,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,59593282,HO,,,59593282,1,20051010,20051021,,,59593282,1,HIV infection
6049025,604902517,17,F,20060216,20190821,20060519,20190830,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,56,KG,20190830,,OT,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,604902517,OT,,,604902517,1,20050523,20050908,,,604902517,1,HIV infection
6078570,60785702,2,F,200606,20190903,20060707,20190905,EXP,,FR-GILEAD-2006-0009829,GILEAD,,43,YR,A,F,Y,,,20190905,,MD,FR,FR,SUSTIVA,Acute kidney injury;Cholelithiasis;Hepatomegaly;Pyelonephritis acute,60785702,HO,,,60785702,1,,20060607,,,60785702,1,HIV infection
7117171,711717112,12,F,,20190904,20090917,20190925,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190925,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,711717112,OT,,,711717112,7,200802,,,,711717112,1,HIV infection
7152253,715225311,11,F,,20190911,20091019,20190924,EXP,,CA-PFIZER INC-2009279889,PFIZER,"PFEFFER, G.. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009;73 (1):71-72",52,YR,,M,Y,,,20190924,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715225311,OT,,,,,,,,,715225311,1,HIV infection
7155921,715592112,12,F,,20190828,20091022,20190911,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, PFEFFER G, COTE H, MONTANER J, LI C, JITRATKOSOL M AND MEZEI M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 JUL 07;73 (1):71-72.",52,YR,,M,Y,,,20190911,,MD,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,715592112,OT,,,,,,,,,715592112,1,HIV infection
8260766,82607669,9,F,2006,20190821,20111123,20190830,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190830,,CN,FR,FR,SUSTIVA,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,82607669,CA,,,82607669,1,20050523,20050908,,,82607669,1,Product used for unknown indication
